BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524. [PMID: 11870363 DOI: 10.1053/jhep.2002.32089] [Cited by in Crossref: 801] [Cited by in F6Publishing: 717] [Article Influence: 42.2] [Reference Citation Analysis]
Number Citing Articles
1 Silva M, Moya A, Berenguer M, Sanjuan F, López-Andujar R, Pareja E, Torres-Quevedo R, Aguilera V, Montalva E, De Juan M. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl. 2008;14:1449-1460. [PMID: 18825681 DOI: 10.1002/lt.21576] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
2 Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology. 2011;81 Suppl 1:158-164. [PMID: 22212951 DOI: 10.1159/000333280] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 7.5] [Reference Citation Analysis]
3 Kim HY, Park JW, Nam BH, Kim HK, Choi JI, Kim TH, Kim HB, Kim CM. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol. 2011;26:1612-1618. [PMID: 21517968 DOI: 10.1111/j.1440-1746.2011.06751.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
4 Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, Tso WK, Fan ST, Poon RT. Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors. Ann Surg Oncol. 2008;15:782-790. [PMID: 18095030 DOI: 10.1245/s10434-007-9733-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
5 Yang J, Yang J, Yan L, Wen T, Li B, Wang W. Hepatic resection vs. transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria with portal hypertension. Digestive and Liver Disease 2018;50:713-9. [DOI: 10.1016/j.dld.2018.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Sukato DC, Tohme S, Chalhoub D, Han K, Zajko A, Amesur N, Orons P, Marsh JW, Geller DA, Tsung A. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization. Journal of Vascular and Interventional Radiology 2015;26:816-824.e1. [DOI: 10.1016/j.jvir.2015.01.038] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
7 Peng BG, Liang LJ, He Q, Kuang M, Lia JM, Lu MD, Huang JF. Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol. 2005;11:700-704. [PMID: 15655825 DOI: 10.3748/wjg.v11.i5.700] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
8 Zhong Y, Deng M, Xu R. Reappraisal of evidence of microscopic portal vein involvement by hepatocellular carcinoma cells with stratification of tumor size. World J Surg 2015;39:1142-9. [PMID: 25270343 DOI: 10.1007/s00268-014-2807-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
9 Jung JM, Chung CK, Kim CH, Yang SH. Minimally Invasive Surgery without Decompression for Hepatocellular Carcinoma Spinal Metastasis with Epidural Spinal Cord Compression Grade 2. J Korean Neurosurg Soc 2019;62:467-75. [PMID: 30919607 DOI: 10.3340/jkns.2018.0199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Thoppil RJ, Bishayee A. Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. World J Hepatol 2011;3:228-49. [PMID: 21969877 DOI: 10.4254/wjh.v3.i9.228] [Cited by in Crossref: 146] [Cited by in F6Publishing: 92] [Article Influence: 14.6] [Reference Citation Analysis]
11 Maruyama H, Kobayashi K, Kiyono S, Ogasawara S, Ooka Y, Suzuki E, Chiba T, Kato N, Komiyama Y, Takawa M, Nagamatsu H, Shiina S. Incidence and hemodynamic feature of risky esophageal varices with lower hepatic venous pressure gradient. Int J Med Sci 2019;16:1614-20. [PMID: 31839749 DOI: 10.7150/ijms.37040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Ye JZ, Chen JZ, Li ZH, Bai T, Chen J, Zhu SL, Li LQ, Wu FX. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. World J Gastroenterol. 2017;23:7415-7424. [PMID: 29151695 DOI: 10.3748/wjg.v23.i41.7415] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 39] [Article Influence: 13.7] [Reference Citation Analysis]
13 Rodriguez-Luna H, Vargas HE, Byrne T, Rakela J. Artificial neural network and tissue genotyping of hepatocellular carcinoma in liver-transplant recipients: prediction of recurrence. Transplantation. 2005;79:1737-1740. [PMID: 15973178 DOI: 10.1097/01.tp.0000161794.32007.d1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 He M, Qin J, Zhai R, Wei X, Wang Q, Rong M, Jiang Z, Huang Y, Zhang Z. Detection and identification of NAP-2 as a biomarker in hepatitis B-related hepatocellular carcinoma by proteomic approach. Proteome Sci 2008;6:10. [PMID: 18331625 DOI: 10.1186/1477-5956-6-10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
15 Pitton MB, Kloeckner R, Herber S, Otto G, Kreitner KF, Dueber C. MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009;15:6044-51. [PMID: 20027676 DOI: 10.3748/wjg.15.6044] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
16 Canellas R, Mehrkhani F, Patino M, Kambadakone A, Sahani D. Characterization of Portal Vein Thrombosis (Neoplastic Versus Bland) on CT Images Using Software-Based Texture Analysis and Thrombus Density (Hounsfield Units). AJR Am J Roentgenol. 2016;207:W81-W87. [PMID: 27490095 DOI: 10.2214/ajr.15.15928] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 5.6] [Reference Citation Analysis]
17 Bannangkoon K, Hongsakul K, Tubtawee T, McNeil E, Sriplung H, Chongsuvivatwong V. Rate and Predictive Factors for Sustained Complete Response after Selective Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2018;19:3545-50. [PMID: 30583681 DOI: 10.31557/APJCP.2018.19.12.3545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Hassoun Z, Gores GJ. Treatment of hepatocellular carcinoma. Clinical Gastroenterology and Hepatology 2003;1:10-8. [DOI: 10.1053/jcgh.2003.50003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
19 Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008;23:467-73. [PMID: 17764529 DOI: 10.1111/j.1440-1746.2007.05112.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
20 Mohanty S, Rajaram R, Bilimoria KY, Salem R, Pawlik TM, Bentrem DJ. Assessment of non-surgical versus surgical therapy for localized hepatocellular carcinoma. J Surg Oncol. 2016;113:175-180. [PMID: 26662882 DOI: 10.1002/jso.24113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
21 Qin Q, Lin YW, Zheng XY, Chen H, Mao QQ, Yang K, Huang SJ, Zhao ZY. RNAa-mediated overexpression of WT1 induces apoptosis in HepG2 cells. World J Surg Oncol 2012;10:11. [PMID: 22244202 DOI: 10.1186/1477-7819-10-11] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
22 Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2006;60:89-98. [DOI: 10.1016/j.critrevonc.2006.06.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 88] [Article Influence: 6.9] [Reference Citation Analysis]
23 Li J, Yan LN, Yang J, Chen ZY, Li B, Zeng Y, Wen TF, Zhao JC, Wang WT, Yang JY. Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients. World J Gastroenterol. 2009;15:4170-4176. [PMID: 19725152 DOI: 10.3748/wjg.15.4170] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
24 Müller C. Hepatocellular carcinoma – Rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006;156:404-9. [DOI: 10.1007/s10354-006-0316-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
25 Wada H, Nagano H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Sakon M, Wakasa K, Monden M. Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-α combination therapy following hepatic resection. J Gastroenterol 2007;42:501-6. [DOI: 10.1007/s00535-007-2028-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
26 Chen CT, Liao LZ, Lu CH, Huang YH, Lin YK, Lin JH, Chow LP. Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells. Exp Mol Med 2020;52:497-513. [PMID: 32203105 DOI: 10.1038/s12276-020-0404-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
27 Zekri AR, Youssef AS, Bakr YM, Gabr RM, Ahmed OS, Elberry MH, Mayla AM, Abouelhoda M, Bahnassy AA. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model. World J Gastroenterol 2016;22:4168-82. [PMID: 27122667 DOI: 10.3748/wjg.v22.i16.4168] [Reference Citation Analysis]
28 Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005;3:75-84. [PMID: 15645408 DOI: 10.1016/s1542-3565(04)00443-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
29 da Silva PH, Gomes MM, de Matos CAL, de Souza E Silva IS, Gonzalez AM, Torres US, Salazar GMM, D'Ippolito G. HCC Detection on Surveillance US: Comparing Focused Liver Protocol Using US LI-RADS Technical Guidelines to a General Complete Abdominal US Protocol. J Ultrasound Med 2021. [PMID: 33463734 DOI: 10.1002/jum.15637] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Cartier V, Boursier J, Lebigot J, Oberti F, Fouchard-hubert I, Aubé C. Radiofrequency ablation of hepatocellular carcinoma: Mono or multipolar?: Radiofrequency ablation of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2016;31:654-60. [DOI: 10.1111/jgh.13179] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
31 Li HH, Qi LN, Ma L, Chen ZS, Xiang BD, Li LQ. Effect of KI-67 positive cellular index on prognosis after hepatectomy in Barcelona Clinic Liver Cancer stage A and B hepatocellular carcinoma with microvascular invasion. Onco Targets Ther 2018;11:4747-54. [PMID: 30127623 DOI: 10.2147/OTT.S165244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Lv L, Chen G, Zhou J, Li J, Gong J. WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1. J Exp Clin Cancer Res. 2015;34:119. [PMID: 26462627 DOI: 10.1186/s13046-015-0233-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
33 Kuo TC, Lu HP, Chao CC. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochem Pharmacol 2011;82:184-94. [PMID: 21549688 DOI: 10.1016/j.bcp.2011.04.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
34 Wang B, Tian L, Gao X, Ma X, Wu J, Zhang C, Zhou Y, Guo W, Yang X. Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection. Clinical Chemistry and Laboratory Medicine (CCLM) 2016;54. [DOI: 10.1515/cclm-2015-1191] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
35 Sánchez-Lorencio MI, Ramirez P, Saenz L, Martínez Sánchez MV, De La Orden V, Mediero-Valeros B, Veganzones-De-Castro S, Baroja-Mazo A, Revilla Nuin B, Gonzalez MR, Cascales-Campos PA, Noguera-Velasco JA, Minguela A, Díaz-Rubio E, Pons JA, Parrilla P. Comparison of Two Types of Liquid Biopsies in Patients With Hepatocellular Carcinoma Awaiting Orthotopic Liver Transplantation. Transplant Proc 2015;47:2639-42. [PMID: 26680058 DOI: 10.1016/j.transproceed.2015.10.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
36 Chu HH, Kim JH, Yoon HK, Ko HK, Gwon DI, Kim PN, Sung KB, Ko GY, Kim SY, Park SH. Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis. J Vasc Interv Radiol. 2019;30:1533-1543. [PMID: 31471190 DOI: 10.1016/j.jvir.2019.06.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
37 Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. [PMID: 19908093 DOI: 10.1007/s00270-009-9711-7] [Cited by in Crossref: 948] [Cited by in F6Publishing: 738] [Article Influence: 79.0] [Reference Citation Analysis]
38 Margarit C, Escartín A, Castells L, Vargas V, Allende E, Bilbao I. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl 2005;11:1242-51. [DOI: 10.1002/lt.20398] [Cited by in Crossref: 154] [Cited by in F6Publishing: 138] [Article Influence: 9.6] [Reference Citation Analysis]
39 Sherman M, Klein A. AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology 2004;40:1465-73. [PMID: 15565604 DOI: 10.1002/hep.20528] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
40 Dollinger MM, Behrens CM, Lesske J, Behl S, Behrmann C, Fleig WE. Thymostimulin in advanced hepatocellular carcinoma: a phase II trial. BMC Cancer 2008;8:72. [PMID: 18366627 DOI: 10.1186/1471-2407-8-72] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
41 Burns JM, Greene FL. Controversies in staging of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2005;12:456-62. [DOI: 10.1007/s00534-005-1030-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
42 Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee DY, Chon CY, Moon YM, Han K. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007;110:129-37. [DOI: 10.1002/cncr.22759] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
43 Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol. 2004;41:864-880. [PMID: 15519663 DOI: 10.1016/j.jhep.2004.09.006] [Cited by in Crossref: 250] [Cited by in F6Publishing: 220] [Article Influence: 15.6] [Reference Citation Analysis]
44 Wu TH, Yu MC, Chen TC, Lee CF, Chan KM, Wu TJ, Chou HS, Lee WC, Chen MF. Encapsulation is a significant prognostic factor for better outcome in large hepatocellular carcinoma. J Surg Oncol. 2012;105:85-90. [PMID: 22161900 DOI: 10.1002/jso.22060] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
45 Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B, Brouquet A, Adams RB; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:289-299. [PMID: 20590901 DOI: 10.1111/j.1477-2574.2010.00181.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 91] [Article Influence: 11.1] [Reference Citation Analysis]
46 Chang WT, Kao WY, Chau GY, Su CW, Lei HJ, Wu JC, Hsia CY, Lui WY, King KL, Lee SD. Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery. 2012;152:809-820. [PMID: 22766361 DOI: 10.1016/j.surg.2012.03.024] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 6.8] [Reference Citation Analysis]
47 Hu H, Chen GF, Yuan W, Wang JH, Zhai B. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis. Int J Hyperthermia 2018;34:1351-8. [PMID: 29720001 DOI: 10.1080/02656736.2018.1462536] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
48 Corona-Villalobos CP, Halappa VG, Geschwind JF, Bonekamp S, Reyes D, Cosgrove D, Pawlik TM, Kamel IR. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol. 2015;25:380-390. [PMID: 25226843 DOI: 10.1007/s00330-014-3412-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
49 Lopez LJ, Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2004;20:248-53. [DOI: 10.1097/00001574-200405000-00009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
50 Lerut J. Carcinome hépatocellulaire et transplantation hépatique : état des lieux. Journal de Chirurgie 2007;144:105-10. [DOI: 10.1016/s0021-7697(07)89481-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Avolio AW, Cillo U, Salizzoni M, De Carlis L, Colledan M, Gerunda GE, Mazzaferro V, Tisone G, Romagnoli R, Caccamo L, Rossi M, Vitale A, Cucchetti A, Lupo L, Gruttadauria S, Nicolotti N, Burra P, Gasbarrini A, Agnes S; On behalf of the Donor‐to‐Recipient Italian Liver Transplant (D2R‐ILTx) Study Group. Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D‐MELD With Particular Reference to HCV Recipients. American Journal of Transplantation 2011;11:2724-36. [DOI: 10.1111/j.1600-6143.2011.03732.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 7.3] [Reference Citation Analysis]
52 Laube R, Sabih AH, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma.J Gastroenterol Hepatol. 2021;36:618-628. [PMID: 32627853 DOI: 10.1111/jgh.15169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
53 Medhat E, Abdel Aziz A, Nabeel M, Elbaz T, Zakaria Z, Shousha H, Amer A, Fouad Fathalah W, Maher R, Musa S. Value of microwave ablation in treatment of large lesions of hepatocellular carcinoma. J Dig Dis. 2015;16:456-463. [PMID: 25958973 DOI: 10.1111/1751-2980.12259] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
54 Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, Fausto N, Bruix J, Carithers RL, Katze MG. Hepatitis C virus and liver disease: Global transcriptional profiling and identification of potential markers. Hepatology;38:1458-67. [DOI: 10.1016/j.hep.2003.09.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 60] [Article Influence: 1.6] [Reference Citation Analysis]
55 Li ZL, Yu JJ, Guo JW, Sui CJ, Dai BH, Zhang WG, Chen TH, Li C, Gu WM, Zhou YH, Wang H, Zhang YM, Mao XH, Pawlik TM, Wang MD, Liang L, Wu H, Lau WY, Wu MC, Shen F, Yang T. Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients. Eur J Surg Oncol 2019;45:800-7. [PMID: 30594407 DOI: 10.1016/j.ejso.2018.12.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
56 Huang J, Hernandez-Alejandro R, Croome KP, Zeng Y, Wu H, Chen Z. Hepatic resection for huge (>15 cm) multinodular HCC with macrovascular invasion. J Surg Res. 2012;178:743-750. [PMID: 22656039 DOI: 10.1016/j.jss.2012.04.058] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
57 Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003;39 Suppl 1:S59-63. [PMID: 14708679 DOI: 10.1016/s0168-8278(03)00140-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
58 Zhang X, Wan JX, Ke ZP, Wang F, Chai HX, Liu JQ. TMEM88, CCL14 and CLEC3B as prognostic biomarkers for prognosis and palindromia of human hepatocellular carcinoma. Tumour Biol 2017;39:1010428317708900. [PMID: 28718365 DOI: 10.1177/1010428317708900] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
59 Ettorre GM, Levi Sandri GB, Colasanti M, Mascianà G, de Werra E, Santoro R, Lepiane P, Montalbano M, Antonini M, Vennarecci G. Liver resection for hepatocellular carcinoma ≥5 cm. Transl Gastroenterol Hepatol 2017;2:22. [PMID: 28447057 DOI: 10.21037/tgh.2017.03.13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
60 Gaba RC, Jin B, Wang D, Lewandowski RJ, Ragin AB, Larson AC, Salem R, Omary RA. Locoregional Chemoembolic Delivery: Prediction With Transcatheter Intraarterial Perfusion MRI. American Journal of Roentgenology 2012;198:1196-202. [DOI: 10.2214/ajr.11.7412] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
61 Kondo T, Maruyama H, Kiyono S, Sekimoto T, Shimada T, Takahashi M, Okugawa H, Yokosuka O, Kawahira H, Yamaguchi T. Eradication of esophageal varices by sclerotherapy combined with argon plasma coagulation: Effect of portal hemodynamics and longitudinal clinical course. Dig Endosc. 2016;28:152-161. [PMID: 26505617 DOI: 10.1111/den.12562] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 O'malley ME, Takayama Y, Sherman M. Outcome of Small (10-20 mm) Arterial Phase-Enhancing Nodules Seen on Triphasic Liver CT in Patients with Cirrhosis or Chronic Liver Disease. Am J Gastroenterology 2005;100:1523-8. [DOI: 10.1111/j.1572-0241.2005.41814.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
63 Yigit T, Yiğitler C, Demiriz M, Arslan I, Tufan T. Hepatocellular carcinoma in the common bile duct "Hepatocellular Carcinoma". Liver Int 2007;27:288-90. [DOI: 10.1111/j.1478-3231.2006.01421.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
64 Brizzi MP, Pignataro D, Tampellini M, Scagliotti GV, Di Maio M. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? Expert Rev Anticancer Ther. 2016;16:1053-1062. [PMID: 27548441 DOI: 10.1080/14737140.2016.1227706] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
65 Song I, Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol. 2009;19:2630-2640. [PMID: 19557416 DOI: 10.1007/s00330-009-1463-x] [Cited by in Crossref: 118] [Cited by in F6Publishing: 89] [Article Influence: 9.8] [Reference Citation Analysis]
66 Chan AK, Hegarty C, Klass D, Yoshida E, Chung S, Liu DM, Ho SG, Harris AC. The Role of Contrast-Enhanced Ultrasound in Guiding Radiofrequency Ablation of Hepatocellular Carcinoma. Can Assoc Radiol J 2015;66:171-8. [DOI: 10.1016/j.carj.2014.11.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
67 Shi M, Chen JA, Lin XJ, Guo RP, Yuan YF, Chen MS, Zhang YQ, Li JQ. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol. 2010;16:264-269. [PMID: 20066748 DOI: 10.3748/wjg.v16.i2.264] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
68 Peng ZW, Chen MS. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma. Oncology. 2013;84 Suppl 1:40-43. [PMID: 23428857 DOI: 10.1159/000345888] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
69 Nouri YM, Kim JH, Yoon HK, Ko HK, Shin JH, Gwon DI. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma. Korean J Radiol 2019;20:34-49. [PMID: 30627020 DOI: 10.3348/kjr.2018.0088] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
70 Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
71 Meza-junco J, Montaño-loza A, Candelaria-myrna. Modalidades de tratamiento para pacientes con carcinoma hepatocelular: una serie retrospectiva de una sola institución en México. Gastroenterología y Hepatología 2004;27:11-7. [DOI: 10.1016/s0210-5705(03)70438-5] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
72 Farinati F, Marino D, Giorgio M, Trevisani F. A reappraisal of the Barcelona Clinic Liver Cancer model: natural history of untreated 'intermediate stage' hepatocellular carcinoma. J Intern Med 2004;256:529-30. [DOI: 10.1111/j.1365-2796.2004.01409.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Wang Z, Peng Y, Hu J, Wang X, Sun H, Sun J, Shi Y, Xiao Y, Ding Z, Yang X, Tang M, Tang Z, Wang J, Lau WY, Fan J, Zhou J. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients. Ann Surg. 2018;. [PMID: 29995681 DOI: 10.1097/sla.0000000000002942] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
74 Li M, He J, Pan M, Yu Y, Pan Z, Xu B, Zhu J. Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3-5cm: A propensity score matching study. Dig Liver Dis. 2016;48:1082-1087. [PMID: 27365224 DOI: 10.1016/j.dld.2016.06.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
75 Zhang X, Lin X, Qiu H, Peng Z. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres® Microspheres in treating Chinese hepatocellular carcinoma patients. J Clin Lab Anal 2019;33:e22975. [PMID: 31328832 DOI: 10.1002/jcla.22975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
76 Adhoute X, Penaranda G, Bronowicki J, Raoul J. Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort. Journal of Hepatology 2015;62:492-3. [DOI: 10.1016/j.jhep.2014.08.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
77 Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S, Amado R, Nuesse B, Durazo F, Han S. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl. 2003;9:672-681. [PMID: 12827551 DOI: 10.1053/jlts.2003.50120] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 2.9] [Reference Citation Analysis]
78 Patwardhan V, Paul S, Corey KE, Mazhar SM, Richter JM, Thiim M, Chung RT. Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. Dig Dis Sci. 2011;56:3316-3322. [PMID: 21805170 DOI: 10.1007/s10620-011-1836-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
79 Hou YF, Li B, Wei YG, Yang JY, Wen TF, Xu MQ, Yan LV, Chen KF. Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria. Medicine (Baltimore) 2015;94:e2070. [PMID: 26632890 DOI: 10.1097/MD.0000000000002070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
80 Greco E, Nanji S, Bromberg IL, Shah S, Wei AC, Moulton CA, Greig PD, Gallinger S, Cleary SP. Predictors of peri-opertative morbidity and liver dysfunction after hepatic resection in patients with chronic liver disease. HPB (Oxford). 2011;13:559-565. [PMID: 21762299 DOI: 10.1111/j.1477-2574.2011.00329.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
81 Shim JH, Park JW, Choi JI, Kim HB, Lee WJ, Kim CM. Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma? J Vasc Interv Radiol. 2009;20:209-216. [PMID: 19084432 DOI: 10.1016/j.jvir.2008.10.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
82 Uenishi T, Nishiguchi S, Tanaka S, Yamamoto T, Takemura S, Kubo S. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2008;98:358-62. [PMID: 18646001 DOI: 10.1002/jso.21111] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
83 Northup PG, Abecassis MM, Englesbe MJ, Emond JC, Lee VD, Stukenborg GJ, Tong L, Berg CL; Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost. Liver Transpl 2009;15:148-62. [PMID: 19177435 DOI: 10.1002/lt.21671] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
84 Vauthey J, Ajani JA. Liver Transplantation and Hepatocellular Carcinoma Biology: Beginning of the End of the Era of Educated Guesses. JCO 2003;21:4265-7. [DOI: 10.1200/jco.2003.07.979] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
85 Xu M, Zheng YL, Xie XY, Liang JY, Pan FS, Zheng SG, Lü MD. Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells. DNA Cell Biol. 2014;33:275-281. [PMID: 24611881 DOI: 10.1089/dna.2013.2184] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
86 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys. 2012;63:159-169. [PMID: 22477032 DOI: 10.1007/s12013-012-9353-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
87 Sartorius K, Sartorius B, Aldous C, Govender PS, Madiba TE. Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol. 2015;39:284-290. [PMID: 25922178 DOI: 10.1016/j.canep.2015.04.006] [Cited by in Crossref: 75] [Cited by in F6Publishing: 57] [Article Influence: 12.5] [Reference Citation Analysis]
88 Hsu CY, Huang YH, Su CW, Lin HC, Chiang JH, Lee PC, Lee FY, Huo TI, Lee SD. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int. 2010;30:77-84. [PMID: 19818004 DOI: 10.1111/j.1478-3231.2009.02128.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
89 Helton WS, Strasberg SM. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: rationale and overview of the conference. HPB (Oxford) 2003;5:238-42. [PMID: 18332994 DOI: 10.1080/13651820310015824] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
90 Padma S, Martinie JB, Iannitti DA. Liver tumor ablation: Percutaneous and open approaches. J Surg Oncol. 2009;100:619-634. [PMID: 20017157 DOI: 10.1002/jso.21364] [Cited by in Crossref: 68] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
91 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3682] [Article Influence: 256.5] [Reference Citation Analysis]
92 Schwartz M, D'amico F, Vitale A, Emre S, Cillo U. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid? European Journal of Surgical Oncology (EJSO) 2008;34:256-62. [DOI: 10.1016/j.ejso.2007.07.208] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
93 Ye M, Qian Y, Tang J, Hu H, Sui M, Shen Y. Targeted biodegradable dendritic MRI contrast agent for enhanced tumor imaging. J Control Release 2013;169:239-45. [PMID: 23403397 DOI: 10.1016/j.jconrel.2013.01.034] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
94 Toyama T, Hiramatsu N, Yakushijin T, Oze T, Nakanishi F, Yasumaru M, Mochizuki K, Kanto T, Takehara T, Kasahara A. A new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution. J Clin Gastroenterol. 2008;42:317-322. [PMID: 18223490 DOI: 10.1097/mcg.0b013e3180ebe790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
95 Végső G, Görög D, Fehérvári I, Nemes B, Doros A, Langer RM, Kóbori L. Role of Organ Transplantation in the Treatment of Malignancies – Hepatocellular Carcinoma as the Most Common Tumour Treated with Transplantation. Pathol Oncol Res 2012;18:1-10. [DOI: 10.1007/s12253-011-9441-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
96 Freese K, Seitz T, Dietrich P, Lee SML, Thasler WE, Bosserhoff A, Hellerbrand C. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro. Cancers (Basel) 2019;11:E1587. [PMID: 31635225 DOI: 10.3390/cancers11101587] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
97 Bassanello M, Vitale A, Ciarleglio FA, Brolese A, Zanus G, D'Amico F, Carraro A, Cappuzzo G, Bridda A, Senzolo M, Burra P, Pevere S, D'Amico D, Cillo U. Adjuvant chemotherapy for transplanted hepatocellular carcinoma patients: Impact on survival or HCV recurrence timing. Transplant Proc. 2003;35:2991-2994. [PMID: 14697958 DOI: 10.1016/j.transproceed.2003.10.075] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
98 Hwang S, Lee S, Joh J, Suh K, Kim D. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: Comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005;11:1265-72. [DOI: 10.1002/lt.20549] [Cited by in Crossref: 162] [Cited by in F6Publishing: 142] [Article Influence: 10.1] [Reference Citation Analysis]
99 Hastir JF, Delbauve S, Larbanoix L, Germanova D, Goyvaerts C, Allard J, Laurent S, Breckpot K, Beschin A, Guilliams M, Flamand V. Hepatocarcinoma Induces a Tumor Necrosis Factor-Dependent Kupffer Cell Death Pathway That Favors Its Proliferation Upon Partial Hepatectomy. Front Oncol 2020;10:547013. [PMID: 33178579 DOI: 10.3389/fonc.2020.547013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Wang N, Cao Y, Song W, He K, Li T, Wang J, Xu B, Si HY, Hu CJ, Li AL. Serum peptide pattern that differentially diagnoses hepatitis B virus-related hepatocellular carcinoma from liver cirrhosis. J Gastroenterol Hepatol 2014;29:1544-50. [PMID: 24612022 DOI: 10.1111/jgh.12545] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
101 Zhong JH, Pan LH, Wang YY, Cucchetti A, Yang T, You XM, Ma L, Gong WF, Xiang BD, Peng NF, Wu FX, Li LQ. Optimizing stage of single large hepatocellular carcinoma: A study with subgroup analysis by tumor diameter. Medicine (Baltimore) 2017;96:e6608. [PMID: 28403105 DOI: 10.1097/MD.0000000000006608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
102 Aiolfi R, Sitia G. Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:183-6. [PMID: 27508186 DOI: 10.2147/JHC.S48763] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
103 Li X, Pan Y, Fan R, Jin H, Han S, Liu J, Wu K, Fan D. Adenovirus-delivered CIAPIN1 small interfering RNA inhibits HCC growth in vitro and in vivo. Carcinogenesis. 2008;29:1587-1593. [PMID: 18299278 DOI: 10.1093/carcin/bgn052] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
104 Ahn J, Flamm SL. Hepatocellular carcinoma. Dis Mon 2004;50:556-73. [PMID: 15616490 DOI: 10.1016/j.disamonth.2004.10.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
105 Stokkeland K, Ebrahim F, Ekbom A. Increased risk of esophageal varices, liver cancer, and death in patients with alcoholic liver disease. Alcohol Clin Exp Res. 2010;34:1993-1999. [PMID: 20735371 DOI: 10.1111/j.1530-0277.2010.01289.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
106 Iezzi R, Pompili M, La Torre MF, Campanale MC, Montagna M, Saviano A, Cesario V, Siciliano M, Annicchiarico E, Agnes S, Giuliante F, Grieco A, Rapaccini GL, De Gaetano AM, Gasbarrini A, Bonomo L, HepatoCATT Study Group for the Multidisciplinary Management of HCC. Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Dig Liver Dis. 2015;47:242-248. [PMID: 25577299 DOI: 10.1016/j.dld.2014.12.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
107 Imai Y, Murakami T, Hori M, Fukuda K, Kim T, Marukawa T, Abe H, Kuwabara M, Onishi H, Tsuda K, Sawai Y, Kurokawa M, Hayashi N, Monden M, Nakamura H. Hypervascular hepatocellular carcinoma: Combined dynamic MDCT and SPIO-enhanced MRI versus combined CTHA and CTAP. Hepatol Res 2008;38:147-58. [PMID: 17645518 DOI: 10.1111/j.1872-034X.2007.00210.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
108 Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, Cho SH, Han JY, Lee YS. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233-240. [PMID: 16440357 DOI: 10.1002/hep.21024] [Cited by in Crossref: 138] [Cited by in F6Publishing: 128] [Article Influence: 9.2] [Reference Citation Analysis]
109 Ladrón de Guevara, L, Rojas-macuil P, Sánchez-chávez X, Rossano-garcía, A, Teresa Gorraez-de-la-mora, M, Cervantes-sánchez, G, Orozco-vázquez J, Lemus-velázquez, M, Rosas-zúñiga, L, Erazo-valle, A, Di-silvio M. Hepatocellular carcinoma: Epidemiological profile from a cohort of federal employees in Mexico. Annals of Hepatology 2009;8:212-9. [DOI: 10.1016/s1665-2681(19)31768-5] [Cited by in Crossref: 12] [Article Influence: 1.0] [Reference Citation Analysis]
110 Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol. 2009;24:806-814. [PMID: 19207681 DOI: 10.1111/j.1440-1746.2008.05728.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 89] [Article Influence: 8.2] [Reference Citation Analysis]
111 Sharr WW, Chan SC, Lo CM. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation. 2014;97 Suppl 8:S10-S17. [PMID: 24849822 DOI: 10.1097/01.tp.0000446267.19148.21] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
112 von Weizsäcker F, Blum HE. Out of control: hepatitis B reactivation by transarterial treatment of hepatocellular carcinoma. J Hepatol. 2004;41:482-484. [PMID: 15336452 DOI: 10.1016/j.jhep.2004.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
113 Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J; for the Barcelona Cly'nic Liver Cancer (BCLC) Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-60. [DOI: 10.1002/hep.20465] [Cited by in Crossref: 330] [Cited by in F6Publishing: 271] [Article Influence: 19.4] [Reference Citation Analysis]
114 Salem DS, Sliem MA, El-sesy M, Shouman SA, Badr Y. Improved chemo-photothermal therapy of hepatocellular carcinoma using chitosan-coated gold nanoparticles. Journal of Photochemistry and Photobiology B: Biology 2018;182:92-9. [DOI: 10.1016/j.jphotobiol.2018.03.024] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
115 Yin L, Mu Y, Lin Y, Xia Q. HGFAC expression decreased in liver cancer and its low expression correlated with DNA hypermethylation and poor prognosis. J Cell Biochem 2019;120:9692-9. [PMID: 30635948 DOI: 10.1002/jcb.28247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
116 Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). Liver Transpl 2018;24:369-79. [PMID: 29140601 DOI: 10.1002/lt.24977] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
117 Sun H, Teng M, Liu J, Jin D, Wu J, Yan D, Fan J, Qin X, Tang H, Peng Z. FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria. Cancer Lett. 2011;306:214-222. [PMID: 21482449 DOI: 10.1016/j.canlet.2011.03.009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
118 Sung JJY, Ng EKW, Lin J, Ho KY, Ji J, Sugano K, Poon RTP, Chan ATC, Goh K, Han K, Chen LLT, Wu K, Ng SSM, Bresalier RS, Chan FKL; the Asia Pacific GI Oncology Summit Group. Digestive cancer management in Asia: Position statements: A report on GI Oncology Summit in 2011: Digestive cancer management in Asia. Journal of Gastroenterology and Hepatology 2012;27:1417-22. [DOI: 10.1111/j.1440-1746.2012.07194.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
119 Blum HE. Treatment of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2005;19:129-45. [DOI: 10.1016/j.bpg.2004.11.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
120 Shin SK, Kim YS, Shim YS, Choi SJ, Park SH, Jung DH, Kwon OS, Choi DJ, Kim JH. Peritumoral decreased uptake area of gadoxetic acid enhanced magnetic resonance imaging and tumor recurrence after surgical resection in hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore) 2017;96:e7761. [PMID: 28816953 DOI: 10.1097/MD.0000000000007761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
121 Majno P, Mentha G, Mazzaferro V. Resection, transplantation, either, or both? Other pieces of the puzzle. Liver Transpl 2005;11:1177-80. [DOI: 10.1002/lt.20495] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
122 Sindram D, Lau KN, Martinie JB, Iannitti DA. Hepatic tumor ablation. Surg Clin North Am. 2010;90:863-876. [PMID: 20637953 DOI: 10.1016/j.suc.2010.04.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
123 Liang L, Xing H, Zhang H, Zhong J, Li C, Lau WY, Wu M, Shen F, Yang T. Surgical resection vs transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford). 2018;20:110-119. [PMID: 29174493 DOI: 10.1016/j.hpb.2017.10.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
124 Oikawa T, Ojima H, Yamasaki S, Takayama T, Hirohashi S, Sakamoto M. Multistep and multicentric development of hepatocellular carcinoma: histological analysis of 980 resected nodules. J Hepatol. 2005;42:225-229. [PMID: 15664248 DOI: 10.1016/j.jhep.2004.10.024] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
125 Xu X, Liu C, Qu K, Song Y, Zhang P, Zhang Y. Liver transplantation versus liver resection for hepatocellular carcinoma: a meta-analysis. Hepatobiliary & Pancreatic Diseases International 2014;13:234-41. [DOI: 10.1016/s1499-3872(14)60037-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
126 Allen J, Venook A. Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep 2004;6:177-83. [PMID: 15066228 DOI: 10.1007/s11912-004-0047-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
127 Li JK, Liu XH, Cui H, Xie XH. Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis. Mol Clin Oncol 2020;12:15-22. [PMID: 31814972 DOI: 10.3892/mco.2019.1941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
128 Blum M, Mueller C, Peck‐radosavljevic M, Wrba F, Berlakovich G, Mühlbacher F, Steiniger R, Speiser M, Pones M, Hüpfl M, Lammer J, Kettenbach J. MR‐guided percutaneous ethanol ablation of hepatocellular carcinomas before liver transplantation. Minimally Invasive Therapy & Allied Technologies 2009;16:230-40. [DOI: 10.1080/13645700701520677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
129 Garcia-retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, Bruguera M, Fuster J, Garcia-valdecasas JC, Rimola A. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004;40:699-707. [DOI: 10.1002/hep.20357] [Cited by in Crossref: 157] [Cited by in F6Publishing: 122] [Article Influence: 9.2] [Reference Citation Analysis]
130 Chen R, Sain NM, Harlow KT, Chen YJ, Shires PK, Heller R, Beebe SJ. A protective effect after clearance of orthotopic rat hepatocellular carcinoma by nanosecond pulsed electric fields. Eur J Cancer. 2014;50:2705-2713. [PMID: 25081978 DOI: 10.1016/j.ejca.2014.07.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
131 Luna LE, Kwo PY, Roberts LR, Mettler TA, Gansen DN, Andrews JC, Wiseman GA, Misra VL. Liver transplantation after radioembolization in a patient with unresectable HCC. Nat Rev Gastroenterol Hepatol 2009;6:679-83. [PMID: 19881519 DOI: 10.1038/nrgastro.2009.165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
132 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Reference Citation Analysis]
133 Wang Y, Deng T, Zeng L, Chen W. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis. Hepatol Res. 2016;46:58-71. [PMID: 26265000 DOI: 10.1111/hepr.12568] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
134 Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot F, Roumilhac D, Canva V, Paris J, Chaput J, Naveau S. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma: META-ANALYSIS: ADJUVANT THERAPY AFTER CURATIVE LIVER RESECTION FOR HCC. Alimentary Pharmacology & Therapeutics 2003;17:1247-61. [DOI: 10.1046/j.1365-2036.2003.01580.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 4.2] [Reference Citation Analysis]
135 Song Y, Wu G, Zhang M, Kong Q, Du J, Zheng Y, Yue L, Cao L. N-myc downstream-regulated gene 1 inhibits the proliferation and invasion of hepatocellular carcinoma cells via the regulation of integrin β3. Oncol Lett 2017;13:3599-607. [PMID: 28521460 DOI: 10.3892/ol.2017.5924] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
136 Huang J, Zhang Y, Chen M, Huang J, Xu L, Chen M. Family history of hepatocellulcar carcinoma is not associated with its patients' prognosis after hepatectomy. World J Surg Oncol 2013;11:280. [PMID: 24134117 DOI: 10.1186/1477-7819-11-280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
137 Kim H, Park MS, Park YN, Kim H, Kim KS, Choi JS, Ahn SH, Han KH, Kim MJ, Kim KW. Preoperative radiologic and postoperative pathologic risk factors for early intra-hepatic recurrence in hepatocellular carcinoma patients who underwent curative resection. Yonsei Med J 2009;50:789-95. [PMID: 20046419 DOI: 10.3349/ymj.2009.50.6.789] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
138 Abbasoglu O. Liver transplantation: yesterday, today and tomorrow. World J Gastroenterol. 2008;14:3117-3122. [PMID: 18506914 DOI: 10.3748/wjg.14.3117] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
139 Couto OFM, Dvorchik I, Carr BI. Causes of Death in Patients with Unresectable Hepatocellular Carcinoma. Dig Dis Sci 2007;52:3285-9. [DOI: 10.1007/s10620-007-9750-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
140 Wang WL, Zheng XL, Zhang ZY, Zhou Y, Hao J, Tang G, Li O, Xiang JX, Wu Z, Wang B. Preoperative γ-glutamyl transpeptidase to platelet ratio (GPR) is an independent prognostic factor for HBV-related hepatocellular carcinoma after curative hepatic resection. Medicine (Baltimore) 2016;95:e4087. [PMID: 27399101 DOI: 10.1097/MD.0000000000004087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
141 Liang L, Chen TH, Li C, Xing H, Han J, Wang MD, Zhang H, Lau WY, Wu MC, Shen F, Yang T. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford). 2018;20:1119-1129. [PMID: 30056066 DOI: 10.1016/j.hpb.2018.06.1804] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
142 Hsu CY, Lee YH, Liu PH, Hsia CY, Huang YH, Lin HC, Chiou YY, Lee FY, Huo TI. Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model. PLoS One 2014;9:e89373. [PMID: 24586728 DOI: 10.1371/journal.pone.0089373] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
143 Ziogas IA, Sioutas G, Mylonas KS, Tsoulfas G. Role of MicroRNA in the Diagnosis and Management of Hepatocellular Carcinoma. Microrna 2020;9:25-40. [PMID: 31218966 DOI: 10.2174/2211536608666190619155406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
144 Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1217-1226. [PMID: 20594247 DOI: 10.1111/j.1440-1746.2010.06335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
145 Seinstra BA, van Delden OM, van Erpecum KJ, van Hillegersberg R, Mali WP, van den Bosch MA. Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? Insights Imaging. 2010;1:167-181. [PMID: 23100194 DOI: 10.1007/s13244-010-0027-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
146 Robinson A, Tavakoli H, Liu B, Bhuket T, Wong RJ. Advanced Hepatocellular Carcinoma Tumor Stage at Diagnosis in the 1945-1965 Birth Cohort Reflects Poor Use of Hepatocellular Carcinoma Screening. Hepatol Commun 2018;2:1147-55. [PMID: 30202827 DOI: 10.1002/hep4.1236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
147 Ramacciato G, Mercantini P, Petrucciani N, Ravaioli M, Cucchetti A, Del Gaudio M, Cescon M, Ziparo V, Pinna AD. Does Surgical Resection Have a Role in the Treatment of Large or Multinodular Hepatocellular Carcinoma? The American Surgeon 2010;76:1189-97. [DOI: 10.1177/000313481007601116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
148 Mizumoto M, Tokuuye K, Sugahara S, Nakayama H, Fukumitsu N, Ohara K, Abei M, Shoda J, Tohno E, Minami M. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys. 2008;71:462-467. [PMID: 18243571 DOI: 10.1016/j.ijrobp.2007.09.056] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 5.5] [Reference Citation Analysis]
149 Liu PH, Su CW, Hsu CY, Hsia CY, Lee YH, Huang YH, Lee RC, Lin HC, Huo TI. Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS One. 2016;11:e0155588. [PMID: 27176037 DOI: 10.1371/journal.pone.0155588] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
150 Scheurlen M, Brambs H, Gassel H. Hepatocellular Carcinoma. In: Scheppach W, Bresalier RS, Tytgat GNJ, editors. Gastrointestinal and Liver Tumors. Berlin: Springer Berlin Heidelberg; 2004. pp. 261-79. [DOI: 10.1007/978-3-642-18629-5_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Chern MC, Chuang VP, Liang CT, Lin ZH, Kuo TM. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors. J Vasc Interv Radiol. 2014;25:32-40. [PMID: 24290099 DOI: 10.1016/j.jvir.2013.10.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
152 Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1:10. [PMID: 24252133 DOI: 10.1186/2050-7771-1-10] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
153 Cho YB, Lee KU, Lee HW, Cho EH, Yang SH, Cho JY, Yi NJ, Suh KS. Outcomes of hepatic resection for a single large hepatocellular carcinoma. World J Surg. 2007;31:795-801. [PMID: 17345125 DOI: 10.1007/s00268-006-0359-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
154 Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S. Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria: Rationale for partial hepatectomy as first strategy. J Am Coll Surg. 2007;204:1-6. [PMID: 17189106 DOI: 10.1016/j.jamcollsurg.2006.10.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
155 Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podesta E, Romagnoli P. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569. [PMID: 12823161 DOI: 10.1046/j.1365-2036.2003.01647.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
156 Namur J, Citron SJ, Sellers MT, Dupuis MH, Wassef M, Manfait M, Laurent A. Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J Hepatol. 2011;55:1332-1338. [PMID: 21703190 DOI: 10.1016/j.jhep.2011.03.024] [Cited by in Crossref: 108] [Cited by in F6Publishing: 88] [Article Influence: 10.8] [Reference Citation Analysis]
157 Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y. Contrast-enhanced sonography-guided radiofrequency ablation for the local recurrence of previously treated hepatocellular carcinoma undetected by B-mode sonography. J Clin Ultrasound. 2010;38:339-345. [PMID: 20572066 DOI: 10.1002/jcu.20720] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
158 Latteri F, Sandonato L, Di Marco V, Parisi P, Cabibbo G, Lombardo G, Galia M, Midiri M, Latteri MA, Craxì A. Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. Dig Liver Dis. 2008;40:684-689. [PMID: 18294940 DOI: 10.1016/j.dld.2007.12.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
159 Liu WT, Lu X, Tang GH, Ren JJ, Liao WJ, Ge PL, Huang JF. LncRNAs expression signatures of hepatocellular carcinoma revealed by microarray. World J Gastroenterol. 2014;20:6314-6321. [PMID: 24876753 DOI: 10.3748/wjg.v20.i20.6314] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
160 Lin DX, Zhang QY, Li X, Ye QW, Lin F, Li LL. An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus. J Cancer Res Clin Oncol. 2011;137:139-149. [PMID: 20340033 DOI: 10.1007/s00432-010-0868-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
161 Liang HY, Guo QY, Sun W, Mao XN, Wen F, Shan M, Zhao G, Wang XH, Lu ZM. Sequential Use of Transhepatic Arterial Chemoembolization and Bipolar Radiofrequency Ablation in the Clinical Therapy of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2015;30:427-32. [PMID: 26683133 DOI: 10.1089/cbr.2015.1884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
162 Tufail K, Araya V, Azhar A, Hertzog D, Khanmoradi K, Ortiz J. Paraparesis caused by transarterial chemoembolization: A case report. World J Hepatol. 2010;2:289-291. [PMID: 21161010 DOI: 10.4254/wjh.v2.i7.289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
163 Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, Nagase M, Nihei K, Ogino T. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol. 2005;23:1839-1846. [PMID: 15774777 DOI: 10.1200/jco.2005.00.620] [Cited by in Crossref: 152] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
164 Wakai T, Shirai Y, Suda T, Yokoyama N, Sakata J, Cruz PV, Kawai H, Matsuda Y, Watanabe M, Aoyagi Y. Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma < or =4 cm. World J Gastroenterol. 2006;12:546-552. [PMID: 16489666 DOI: 10.3748/wjg.v12.i4.546] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
165 Wang X, Wang Z, Wu L. Combined measurements of tumor number and size helps estimate the outcome of resection of Barcelona clinic liver cancer stage B hepatocellular carcinoma. BMC Surg. 2016;16:22. [PMID: 27094483 DOI: 10.1186/s12893-016-0135-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
166 White JA, Gray SH, Li P, Simpson HN, McGuire BM, Eckhoff DE, Abdel Aal AMK, Saddekni S, Dubay DA. Current guidelines for chemoembolization for hepatocellular carcinoma: Room for improvement? Hepatol Commun 2017;1:338-46. [PMID: 29404463 DOI: 10.1002/hep4.1046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
167 Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018;10:336-43. [PMID: 30364796 DOI: 10.4251/wjgo.v10.i10.336] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
168 El-Fattah MA. Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA. Indian J Gastroenterol. 2017;36:117-125. [PMID: 28194604 DOI: 10.1007/s12664-017-0732-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
169 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 644] [Article Influence: 62.2] [Reference Citation Analysis]
170 Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, Block TM, Marrero JA, Drake RR. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology. 2005;41:634-642. [PMID: 15726646 DOI: 10.1002/hep.20577] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 6.6] [Reference Citation Analysis]
171 Farrell C, Halpen A, Cross TJ, Richardson PD, Johnson P, Joekes EC. Ultrasound surveillance for hepatocellular carcinoma: service evaluation of a radiology-led recall system in a tertiary-referral centre for liver diseases in the UK. Clin Radiol. 2017;72:338.e11-338.e17. [PMID: 28041651 DOI: 10.1016/j.crad.2016.10.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
172 Puneet P, Perera MTPR, Mirza DF. Current opinion on the role of resection and liver transplantation for hepatocellular cancer. Indian J Gastroenterol 2012;31:89-99. [DOI: 10.1007/s12664-012-0200-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
173 Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009;15:3210-6. [PMID: 19598295 DOI: 10.3748/wjg.15.3210] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 86] [Article Influence: 7.8] [Reference Citation Analysis]
174 Kim RD, Reed AI, Fujita S, Foley DP, Mekeel KL, Hemming AW. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg. 2007;205:108-123. [PMID: 17617340 DOI: 10.1016/j.jamcollsurg.2007.02.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
175 Yao FY, Hirose R, LaBerge JM, Davern TJ 3rd, Bass NM, Kerlan RK Jr, Merriman R, Feng S, Freise CE, Ascher NL, Roberts JP. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005;11:1505-14. [PMID: 16315294 DOI: 10.1002/lt.20526] [Cited by in Crossref: 209] [Cited by in F6Publishing: 171] [Article Influence: 13.9] [Reference Citation Analysis]
176 Takahashi M, Maruyama H, Ishibashi H, Yoshikawa M, Yokosuka O. Contrast-Enhanced Ultrasound With Perflubutane Microbubble Agent: Evaluation of Differentiation of Hepatocellular Carcinoma. American Journal of Roentgenology 2011;196:W123-31. [DOI: 10.2214/ajr.10.4242] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
177 Ding T, Xu J, Wang F, Shi M, Zhang Y, Li SP, Zheng L. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol. 2009;40:381-389. [PMID: 18992916 DOI: 10.1016/j.humpath.2008.08.011] [Cited by in Crossref: 134] [Cited by in F6Publishing: 132] [Article Influence: 10.3] [Reference Citation Analysis]
178 Zheng W, Wang X, Hu J, Bai B, Zhu H. Diverse molecular functions of aspartate β‑hydroxylase in cancer (Review). Oncol Rep 2020;44:2364-72. [PMID: 33125119 DOI: 10.3892/or.2020.7792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
179 Liu Z, Gao F, Yang G, Singh S, Lu M, Zhang T, Zhong Z, Zhang F, Tang R. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol. 2014;35:7407-7413. [PMID: 24777334 DOI: 10.1007/s13277-014-1976-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
180 Li S, Peck-Radosavljevic M, Ubl P, Wadsak W, Mitterhauser M, Rainer E, Pinter M, Wang H, Nanoff C, Kaczirek K, Haug A, Hacker M. The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. Eur J Nucl Med Mol Imaging 2017;44:1732-41. [PMID: 28555333 DOI: 10.1007/s00259-017-3724-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
181 Llovet JM. Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data. Liver Transpl 2006;12:1741-3. [PMID: 17133574 DOI: 10.1002/lt.20908] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
182 Jia Z, Zhang H, Li N. Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta-analysis of recent randomized controlled trials. J Gastroenterol Hepatol 2021;36:1769-77. [PMID: 33569810 DOI: 10.1111/jgh.15440] [Reference Citation Analysis]
183 Majno P, Mazzaferro V. Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: questions, answers and demands for a common language. Liver Transpl. 2006;12:896-898. [PMID: 16721768 DOI: 10.1002/lt.20808] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
184 Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7:35-41. [PMID: 18333159 DOI: 10.1080/13651820410024058] [Cited by in Crossref: 153] [Cited by in F6Publishing: 130] [Article Influence: 13.9] [Reference Citation Analysis]
185 Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, Laubenberger J, Zuber I, Blum HE. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235-240. [PMID: 12759473 DOI: 10.1148/radiol.2281020718] [Cited by in Crossref: 701] [Cited by in F6Publishing: 559] [Article Influence: 38.9] [Reference Citation Analysis]
186 Walzer N, Kulik LM. Hepatocellular carcinoma: latest developments. Curr Opin Gastroenterol 2008;24:312-9. [PMID: 18408459 DOI: 10.1097/MOG.0b013e3282fafef3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
187 Santhakumar C, Gane EJ, Liu K, Mccaughan GW. Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatol Int 2020;14:947-57. [DOI: 10.1007/s12072-020-10104-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
188 García-Valdecasas JC, Fuster J, Charco R, Bombuy E, Fondevila C, Ferrer J, Ayuso C, Taura P. Changes in portal vein flow after adult living-donor liver transplantation: does it influence postoperative liver function? Liver Transpl. 2003;9:564-569. [PMID: 12783396 DOI: 10.1053/jlts.2003.50069] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
189 Lin CT, Hsu KF, Chen TW, Yu JC, Chan DC, Yu CY, Hsieh TY, Fan HL, Kuo SM, Chung KP, Hsieh CB. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg. 2010;34:2155-2161. [PMID: 20407768 DOI: 10.1007/s00268-010-0598-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 5.5] [Reference Citation Analysis]
190 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429-442. [PMID: 12540794 DOI: 10.1053/jhep.2003.50047] [Cited by in Crossref: 2017] [Cited by in F6Publishing: 1715] [Article Influence: 112.1] [Reference Citation Analysis]
191 Xu XS, Qu K, Liu C, Zhang YL, Liu J, Song YZ, Zhang P, Liu SN, Chang HL. Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma. World J Gastroenterol 2012;18:7242-50. [PMID: 23326129 DOI: 10.3748/wjg.v18.i48.7242] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
192 Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002;8:873-883. [PMID: 12360427 DOI: 10.1053/jlts.2002.34923] [Cited by in Crossref: 291] [Cited by in F6Publishing: 268] [Article Influence: 16.2] [Reference Citation Analysis]
193 Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, Mannucci PM; Study Group of the Association of Italian Hemophilia Centers. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003;102:78-82. [PMID: 12649165 DOI: 10.1182/blood-2002-10-3310] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 4.2] [Reference Citation Analysis]
194 Viola C, Asselah T, Samuel D, Durand F, Boudjema H, Valla D, Marcellin P. Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma. World J Gastroenterol 2006;12:4911-3. [PMID: 16937481 DOI: 10.3748/wjg.v12.i30.4911] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
195 Polat KY, Acar S, Gencdal G, Yazar S, Kargi A, Donmez R, Aslan S, Kavlak ME, Arikan C, Akyildiz M. Hepatocellular Carcinoma and Liver Transplantation: A Single-Center Experience. Transplantation Proceedings 2020;52:259-64. [DOI: 10.1016/j.transproceed.2019.10.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
196 Maruyama H, Kobayashi K, Kiyono S, Ogasawara S, Suzuki E, Ooka Y, Chiba T, Yamaguchi T. Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosis. Int J Med Sci 2017;14:804-10. [PMID: 28824317 DOI: 10.7150/ijms.19847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
197 Guariniello S, Di Bernardo G, Colonna G, Cammarota M, Castello G, Costantini S. Evaluation of the selenotranscriptome expression in two hepatocellular carcinoma cell lines. Anal Cell Pathol (Amst) 2015;2015:419561. [PMID: 26199857 DOI: 10.1155/2015/419561] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
198 Toshima T, Shirabe K, Yoshiya S, Muto J, Ikegami T, Yoshizumi T, Maehara Y. Outcome of hepatectomy for hepatocellular carcinoma in patients with renal dysfunction. HPB (Oxford). 2012;14:317-324. [PMID: 22487069 DOI: 10.1111/j.1477-2574.2012.00452.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
199 Kondo T, Maruyama H, Kiyono S, Sekimoto T, Shimada T, Takahashi M, Okugawa H, Kobayashi S, Yoshizumi H, Yokosuka O. Similarities and differences in the clinical features between cardia varices and esophageal varices. J Gastroenterol Hepatol. 2014;29:1911-1918. [PMID: 24909069 DOI: 10.1111/jgh.12647] [Reference Citation Analysis]
200 Hsieh CB, Chou SJ, Shih ML, Chu HC, Chu CH, Yu JC, Yao NS. Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2008;34:906-10. [PMID: 18166289 DOI: 10.1016/j.ejso.2007.11.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
201 Adler M, De Pauw F, Vereerstraeten P, Fancello A, Lerut J, Starkel P, Van Vlierberghe H, Troisi R, Donckier V, Detry O, Delwaide J, Michielsen P, Chapelle T, Pirenne J, Nevens F. Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transpl 2008;14:526-33. [DOI: 10.1002/lt.21399] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
202 Zhang Y, Wang S, Xiao J, Zhou H. Bioinformatics analysis to identify the key genes affecting the progression and prognosis of hepatocellular carcinoma. Biosci Rep. 2019;39. [PMID: 30705088 DOI: 10.1042/bsr20181845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
203 Vergara Gómez M, Miquel Planas M, Gil Prades M, Dalmau Obrador B, Casas Rodrigo M, Sanchez Delgado J, Bella MR, Puig Domingo J. [Rapid progression of hepatocellular carcinoma after surgery: apropos of a case and review of the literature]. Gastroenterol Hepatol 2010;33:569-73. [PMID: 20627456 DOI: 10.1016/j.gastrohep.2010.03.008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
204 Kong JY, Li SM, Fan HY, Zhang L, Zhao HJ, Li SM. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e11872. [PMID: 30113483 DOI: 10.1097/MD.0000000000011872] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
205 Wan L, Dong DH, Wu XN, Ding HF, Lu Q, Tian Y, Zhang XF, Li W. Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B? Med Sci Monit 2020;26:e926797. [PMID: 33060558 DOI: 10.12659/MSM.926797] [Reference Citation Analysis]
206 Yang T, Zhu J, Zhao L, Mai K, Ye J, Huang S, Zhao Y. Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammation-based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resection. J Surg Oncol. 2017;115:718-728. [PMID: 28127774 DOI: 10.1002/jso.24549] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
207 Ren FY, Piao XX, Jin AL. Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma. World J Gastroenterol. 2006;12:4656-4659. [PMID: 16937435 DOI: 10.3748/wjg.v12.i29.4656] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
208 Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 2008;95:611-619. [PMID: 18311747 DOI: 10.1002/bjs.6011] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 5.2] [Reference Citation Analysis]
209 Moon D, Lee S, Hwang S. Liver Transplantation for Hepatocellular Carcinoma: Single Nodule with Child-Pugh Class A Sized Less than 3 cm. Dig Dis 2007;25:320-8. [DOI: 10.1159/000106912] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
210 Moreau R, Delègue P, Pessione F, Hillaire S, Durand F, Lebrec D, Valla DC. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int 2004;24:457-64. [PMID: 15482343 DOI: 10.1111/j.1478-3231.2004.0991.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
211 Tang C, Feng W, Qin L, Bao Y. Chinese Herbal Medicine, Jian Pi Li Gan Decoction, Improved Survival of Nonresectable Hepatocellular Cancer After Radiofrequency Ablation: A Retrospective Study. Integr Cancer Ther 2018;17:431-6. [PMID: 28745082 DOI: 10.1177/1534735417722223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
212 Younis YS, Alegaily HS, Elagawy W, Semeya AA, Abo-Amer YE, El-Abgeegy M, Mostafa SM, Elsergany HF, Abd-Elsalam S. Serum Dickopff 1 as a Novel Biomarker in Hepatocellular Carcinoma Diagnosis and Follow Up After Ablative Therapy. Cancer Manag Res 2019;11:10555-62. [PMID: 31908527 DOI: 10.2147/CMAR.S218532] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
213 Rodriguez-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas HE. Hepatitis C virus infection with hepatocellular carcinoma: not a controversial indication for liver transplantation. Transplantation. 2004;78:580-583. [PMID: 15446318 DOI: 10.1097/01.tp.0000129797.30999.69] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
214 Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 2007;5:508-12. [PMID: 17382601 DOI: 10.1016/j.cgh.2007.01.014] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
215 Shimose S, Kawaguchi T, Iwamoto H, Niizeki T, Shirono T, Tanaka M, Koga H, Torimura T. Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. Oncol Lett 2020;19:2667-76. [PMID: 32218817 DOI: 10.3892/ol.2020.11399] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
216 Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M. Reply to Letter: “Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on ‘Surgical Misinterpretation’ of the BCLC Staging System”: Real Misinterpretation or Lack of Clarity Within the BCLC? Ann Surg. 2015;262:e18-e19. [PMID: 24263335 DOI: 10.1097/sla.0000000000000383] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
217 Vashist YK, Tiffon C, Stoupis C, Redaelli CA. Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. World J Gastroenterol 2006;12:6771-8. [PMID: 17106924 DOI: 10.3748/wjg.v12.i42.6771] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
218 Herman JM, Pawlik TM. Hepatocellular Carcinoma, Gallbladder Cancer, and Cholangiocarcinoma. In: Lu JJ, Brady LW, editors. Radiation Oncology. Berlin: Springer Berlin Heidelberg; 2008. pp. 221-43. [DOI: 10.1007/978-3-540-77385-6_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
219 Chin KM, Allen JC, Teo JY, Kam JH, Tan EK, Koh Y, Goh KPB, Cheow PC, Raj P, Chow KHP, Chung YFA, Ooi LL, Chan CY, Lee SY. Predictors of post-hepatectomy liver failure in patients undergoing extensive liver resections for hepatocellular carcinoma. Ann Hepatobiliary Pancreat Surg 2018;22:185-96. [PMID: 30215040 DOI: 10.14701/ahbps.2018.22.3.185] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
220 Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009;198:313-318. [PMID: 19285298 DOI: 10.1016/j.amjsurg.2008.09.026] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 7.3] [Reference Citation Analysis]
221 Hiramine Y, Uto H, Imamura Y, Tabu K, Baba Y, Hiwaki T, Sho Y, Tahara K, Higashi H, Tamai T. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med. 2011;2:433-441. [PMID: 22977522 DOI: 10.3892/etm.2011.237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
222 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
223 Thein H, Walter SR, Gidding HF, Amin J, Law MG, George J, Dore GJ. Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort: HCC survival in people with hepatitis B or C. Hepatology Research 2012;42:1175-86. [DOI: 10.1111/j.1872-034x.2012.01037.x] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
224 Shim JH, Park J, Choi J, Park BJ, Kim C. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2009;135:617-25. [DOI: 10.1007/s00432-008-0496-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
225 Bruix J. HCC surveillance: Who is the target population? Hepatology 2003;37:507-9. [DOI: 10.1053/jhep.2003.50142] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.2] [Reference Citation Analysis]
226 Maluf D, Fisher RA, Maroney T, Cotterell A, Fulcher A, Tisnado J, Contos M, Luketic V, Stravitz R, Shiffman M. Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy. Am J Transplant. 2003;3:312-317. [PMID: 12614287 DOI: 10.1034/j.1600-6143.2003.00041.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
227 Tranquart F, Claudon M, Correas J. Recommandations pour l’utilisation des agents de contraste ultrasonores. Journal de Radiologie 2005;86:1047-54. [DOI: 10.1016/s0221-0363(05)81492-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
228 Ke L, Shen R, Fan W, Hu W, Shen S, Li S, Kuang M, Liang L, Li J, Peng B, Hua Y. The role of associating liver partition and portal vein ligation for staged hepatectomy in unresectable hepatitis B virus-related hepatocellular carcinoma. Ann Transl Med 2020;8:1402. [PMID: 33313147 DOI: 10.21037/atm-20-2420] [Reference Citation Analysis]
229 Niu ZJ, Ma YL, Kang P, Ou SQ, Meng ZB, Li ZK, Qi F, Zhao C. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol. 2012;29:2992-2997. [PMID: 22200992 DOI: 10.1007/s12032-011-0145-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
230 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 247] [Article Influence: 30.3] [Reference Citation Analysis]
231 Wang K, Liu J, Yan ZL, Li J, Shi LH, Cong WM, Xia Y, Zou QF, Xi T, Shen F, Wang HY, Wu MC. Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 2010;52:164-73. [PMID: 20578260 DOI: 10.1002/hep.23650] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
232 Ratti F, Cipriani F, Paganelli M, Ferla G, Aldrighetti LA. Surgical approach to multifocal hepatocellular carcinoma with portal vein thrombosis and arterioportal shunt leading to portal hypertension and bleeding: a case report. World J Surg Oncol. 2012;10:34. [PMID: 22330617 DOI: 10.1186/1477-7819-10-34] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
233 Liu G, Xia F, Fan G, Yu J, Bao L, Zhang C, Chi R, Zhang T, Wang L, Shen F, Wang D. Type 2 diabetes mellitus worsens the prognosis of intermediate-stage hepatocellular carcinoma after transarterial chemoembolization. Diabetes Res Clin Pract 2020;169:108375. [PMID: 32827592 DOI: 10.1016/j.diabres.2020.108375] [Reference Citation Analysis]
234 Lau KN, Swan RZ, Sindram D, Martinie JB, Iannitti DA. Hepatic tumor ablation: application in a community hospital setting. Surg Oncol Clin N Am 2011;20:455-66, viii. [PMID: 21640915 DOI: 10.1016/j.soc.2011.01.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
235 Chow PK. Resection for hepatocellular carcinoma: is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria? J Gastroenterol Hepatol. 2012;27:452-457. [PMID: 22142283 DOI: 10.1111/j.1440-1746.2011.07034.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
236 Li JW, Goh BG, Chang PE, Tan CK. Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective. World J Gastroenterol. 2017;23:4054-4063. [PMID: 28652658 DOI: 10.3748/wjg.v23.i22.4054] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
237 França AV, Elias Junior J, Lima BL, Martinelli AL, Carrilho FJ. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res. 2004;37:1689-1705. [PMID: 15517086 DOI: 10.1590/s0100-879x2004001100015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
238 Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234:961-967. [PMID: 15665226 DOI: 10.1148/radiol.2343040350] [Cited by in Crossref: 608] [Cited by in F6Publishing: 496] [Article Influence: 38.0] [Reference Citation Analysis]
239 Qu K, Yan Z, Wu Y, Chen Y, Qu P, Xu X, Yuan P, Huang X, Xing J, Zhang H, Liu C, Zhang J. Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma: Chemoembolization aggravated fibrosis. J Gastroenterol Hepatol 2015;30:925-32. [DOI: 10.1111/jgh.12873] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
240 Nakahara H, Itamoto T, Katayama K, Ohdan H, Hino H, Ochi M, Tashiro H, Asahara T. Indication of Hepatectomy for Cirrhotic Patients with Hepatocellular Carcinoma Classified as Child-Pugh Class B. World J Surg 2005;29:734-8. [DOI: 10.1007/s00268-005-7750-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
241 Nakayama H, Sugahara S, Fukuda K, Abei M, Shoda J, Sakurai H, Tsuboi K, Matsuzaki Y, Tokuuye K. Proton Beam Therapy for Hepatocellular Carcinoma Located Adjacent to the Alimentary Tract. International Journal of Radiation Oncology*Biology*Physics 2011;80:992-5. [DOI: 10.1016/j.ijrobp.2010.03.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
242 Yin L, He N, Chen C, Zhang N, Lin Y, Xia Q. Identification of novel blood-based HCC-specific diagnostic biomarkers for human hepatocellular carcinoma. Artif Cells Nanomed Biotechnol 2019;47:1908-16. [PMID: 31072138 DOI: 10.1080/21691401.2019.1613421] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
243 Brouquet A, Andreou A, Shindoh J, Vauthey JN. Methods to improve resectability of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:57-67. [PMID: 22941013 DOI: 10.1007/978-3-642-16037-0_4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
244 Lee A, Rode A, Nicoll A, Maczurek AE, Lim L, Lim S, Angus P, Kronborg I, Arachchi N, Gorelik A, Liew D, Warner FJ, McCaughan GW, McLennan SV, Shackel NA. Circulating CD147 predicts mortality in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:459-66. [PMID: 26312403 DOI: 10.1111/jgh.13148] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
245 Schwartz JD, Llovet JM. Molecular Targeting in Hepatocellular Carcinoma. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 165-210. [DOI: 10.1007/978-1-59745-337-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
246 Li S, Beheshti M, Peck-Radosavljevic M, Oezer S, Grumbeck E, Schmid M, Hamilton G, Kapiotis S, Dudczak R, Kletter K. Comparison of (11)C-acetate positron emission tomography and (67)Gallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver Int 2006;26:920-7. [PMID: 16953831 DOI: 10.1111/j.1478-3231.2006.01335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
247 Jin YJ, Chung YH, Kim JA, Park WH, Lee D, Seo DD, Ryu SH, Jang MK, Yu E, Lee YJ. Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma. Dig Dis Sci. 2012;57:2917-2923. [PMID: 22777614 DOI: 10.1007/s10620-012-2296-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
248 Weber S, Jarnagin W, Duffy A, O'reilly EM, Abou-alfa GK, Blumgart L. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1569-94. [DOI: 10.1016/b978-0-443-06694-8.50088-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
250 Ross SB, Luberice K, Kurian TJ, Paul H, Rosemurgy AS. Defining the learning curve of laparoendoscopic single-site Heller myotomy. Am Surg. 2013;79:837-844. [PMID: 23896255 DOI: 10.1186/1477-7819-11-171] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
251 Yao F. Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transplantation 2002;8:765-74. [DOI: 10.1053/jlts.2002.34892] [Cited by in Crossref: 301] [Cited by in F6Publishing: 261] [Article Influence: 15.8] [Reference Citation Analysis]
252 Ludwig JM, Gai Y, Sun L, Xiang G, Zeng D, Kim HS. SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation. Mol Oncol 2016;10:1133-45. [PMID: 27262893 DOI: 10.1016/j.molonc.2016.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
253 Miszczuk MA, Chapiro J, Geschwind JH, Thakur V, Nezami N, Laage-Gaupp F, Kulon M, van Breugel JMM, Fereydooni A, Lin M, Savic LJ, Tegel B, Wahlin T, Funai E, Schlachter T. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Transl Oncol 2020;13:100742. [PMID: 32092672 DOI: 10.1016/j.tranon.2020.01.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
254 Hwang SH, Yu JS, Kim KW, Kim JH, Chung JJ. Small hypervascular enhancing lesions on arterial phase images of multiphase dynamic computed tomography in cirrhotic liver: fate and implications. J Comput Assist Tomogr. 2008;32:39-45. [PMID: 18303286 DOI: 10.1097/rct.0b013e318064c76b] [Cited by in Crossref: 32] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
255 Hsu MH, Wu SC, Pao KC, Unlu I, Gnabre JN, Mold DE, Huang RC, Hwu JR. Hepatocellular carcinoma targeting agents: conjugates of nitroimidazoles with trimethyl nordihydroguaiaretic acid. ChemMedChem 2014;9:1030-7. [PMID: 24648164 DOI: 10.1002/cmdc.201300521] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
256 Mancuso A, Perricone G. Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol 2014;2:176-81. [PMID: 26357625 DOI: 10.14218/JCTH.2014.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
257 Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, Nakamura S, Kobayashi Y, Araki Y, Aoki N. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol. 2008;23:437-444. [PMID: 17683496 DOI: 10.1111/j.1440-1746.2007.05054.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
258 Lencioni R, Della Pina C, Crocetti L, Cioni D. Percutaneous Ablation of Hepatocellular Carcinoma. In: Stroszczynski C, editor. Minimally Invasive Tumor Therapies. Berlin: Springer Berlin Heidelberg; 2006. pp. 91-105. [DOI: 10.1007/3-540-28137-1_7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
259 Dollinger MM, Lautenschlaeger C, Lesske J, Tannapfel A, Wagner AD, Schoppmeyer K, Nehls O, Welker MW, Wiest R, Fleig WE. Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. BMC Cancer. 2010;10:457. [PMID: 20735834 DOI: 10.1186/1471-2407-10-457] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
260 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
261 Han K, Tzimas GN, Barkun JS, Metrakos P, Tchervenkov JL, Hilzenrat N, Wong P, Deschênes M. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007;21:39-45. [PMID: 17225881 DOI: 10.1155/2007/206383] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 4.0] [Reference Citation Analysis]
262 Lencioni R, Cioni D, Crocetti L, Bartolozzi C. Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl 2004;10:S91-7. [PMID: 14762847 DOI: 10.1002/lt.20043] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
263 Kim SJ, Choi MS, Kang JY, Choi DI, Park CK, Gwak GY, Lee JH, Koh KC, Paik SW, Yoo BC. Prediction of complete necrosis of hepatocellular carcinoma treated with transarterial chemoembolization prior to liver transplantation. Gut Liver 2009;3:285-91. [PMID: 20431762 DOI: 10.5009/gnl.2009.3.4.285] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
264 Zhao YN, Zhang YQ, Ye JZ, Liu X, Yang HZ, Cong FY, Xiang BD, Wu FX, Ma L, Li LQ, Ye HH. Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma. Exp Ther Med 2016;12:3813-9. [PMID: 28105115 DOI: 10.3892/etm.2016.3810] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
265 Shibolet O, Alper R, Zlotogarov L, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer 2003;106:236-43. [PMID: 12800200 DOI: 10.1002/ijc.11201] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
266 Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2009;104:514-524. [PMID: 19174803 DOI: 10.1038/ajg.2008.80] [Cited by in Crossref: 166] [Cited by in F6Publishing: 138] [Article Influence: 13.8] [Reference Citation Analysis]
267 Sun X, Cai Y, Xu Z, Zhu D. Preparation and Properties of Tumor-Targeting MRI Contrast Agent Based on Linear Polylysine Derivatives. Molecules 2019;24:E1477. [PMID: 30991689 DOI: 10.3390/molecules24081477] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
268 Zhou J, Ding T, Pan W, Zhu L, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 2009;125:1640-8. [DOI: 10.1002/ijc.24556] [Cited by in Crossref: 158] [Cited by in F6Publishing: 145] [Article Influence: 13.2] [Reference Citation Analysis]
269 Rimola A, Llovet JM, Navasa M, Bruix J, Londoño M, Fuster J, García-valdecasas J. Applicability of adult-to-adult living donor liver transplantation. Journal of Hepatology 2005;43:104-9. [DOI: 10.1016/j.jhep.2005.02.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
270 Kornberg A, Küpper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, Wilberg J. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: Clinical patterns and outcome variables. European Journal of Surgical Oncology (EJSO) 2010;36:275-80. [DOI: 10.1016/j.ejso.2009.10.001] [Cited by in Crossref: 83] [Cited by in F6Publishing: 62] [Article Influence: 7.5] [Reference Citation Analysis]
271 Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F, PRECISION ITALIA STUDY GROUP. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255-264. [PMID: 24937669 DOI: 10.1038/bjc.2014.199] [Cited by in Crossref: 264] [Cited by in F6Publishing: 214] [Article Influence: 37.7] [Reference Citation Analysis]
272 Guerriero E, Capone F, Accardo M, Sorice A, Costantini M, Colonna G, Castello G, Costantini S. GPX4 and GPX7 over-expression in human hepatocellular carcinoma tissues. Eur J Histochem 2015;59:2540. [PMID: 26708178 DOI: 10.4081/ejh.2015.2540] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
273 Li M, Zhao H, Bi X, Li Z, Huang Z, Han Y, Zhou J, Zhao J, Zhang Y, Wei W, Zhao D, Cai J. Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma. Tumor Biol 2016;37:9301-10. [DOI: 10.1007/s13277-016-4794-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
274 Wei K, Wang M, Zhang W, Mu H, Song TQ. Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Med Oncol. 2014;31:969. [PMID: 24793745 DOI: 10.1007/s12032-014-0969-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
275 Barreto SG, Brooke-Smith M, Dolan P, Wilson TG, Padbury RT, Chen JW. Cirrhosis and microvascular invasion predict outcomes in hepatocellular carcinoma. ANZ J Surg. 2013;83:331-335. [PMID: 22943449 DOI: 10.1111/j.1445-2197.2012.06196.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
276 Wang BW, Mok KT, Liu SI, Chou NH, Tsai CC, Chen IS, Yeh MH, Chen YC. Is hepatectomy beneficial in the treatment of multinodular hepatocellular carcinoma? J Formos Med Assoc. 2008;107:616-626. [PMID: 18678545 DOI: 10.1016/s0929-6646(08)60179-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
277 Sala M, Varela M, Forner A, Bruix J. [Early diagnosis of liver cancer]. Gastroenterol Hepatol 2005;28:292-7. [PMID: 15871814 DOI: 10.1157/13074066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
278 Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH, DeMatteo RP. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003;238:315-21; discussion 321-3. [PMID: 14501497 DOI: 10.1097/01.sla.0000086548.84705.ef.] [Reference Citation Analysis]
279 Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol. 2006;4:252-261. [PMID: 16527686 DOI: 10.1016/j.cgh.2006.01.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
280 Jin YJ, Chung YH, Kim JA, Park W, Lee D, Shim JH, Lee D, Kim KM, Lim YS, Lee HC. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization. Dig Dis Sci. 2013;58:1758-1765. [PMID: 23361574 DOI: 10.1007/s10620-013-2562-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
281 Furukawa H, Shimamura T, Suzuki T, Taniguchi M, Yamashita K, Kamiyama T, Matsushita M, Todo S. Living-donor liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006;13:393-7. [DOI: 10.1007/s00534-005-1079-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
282 Cho ES, Choi JY. MRI features of hepatocellular carcinoma related to biologic behavior. Korean J Radiol. 2015;16:449-464. [PMID: 25995679 DOI: 10.3348/kjr.2015.16.3.449] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
283 Yin W, Zhao Y, Ji YJ, Tong LP, Liu Y, He SX, Wang AQ. Serum/plasma microRNAs as biomarkers for HBV-related hepatocellular carcinoma in China. Biomed Res Int. 2015;2015:965185. [PMID: 25688372 DOI: 10.1155/2015/965185] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
284 Yu Q, Liu Z, Chen Q, Lin J. Mcl-1 as a potential therapeutic target for human hepatocelluar carcinoma. J Huazhong Univ Sci Technol [Med Sci ] 2016;36:494-500. [DOI: 10.1007/s11596-016-1614-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
285 Wan YM, Li YH, Xu ZY, Wu HM, Xu Y, Yang M, Wu XN. The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study. Integr Cancer Ther 2018;17:477-85. [PMID: 29108428 DOI: 10.1177/1534735417734913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
286 Woo HY, Bae SH, Park JY, Han KH, Chun HJ, Choi BG, Im HU, Choi JY, Yoon SK, Cheong JY. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2010;65:373-382. [PMID: 19763572 DOI: 10.1007/s00280-009-1126-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
287 Kondo T, Maruyama H, Sekimoto T, Shimada T, Takahashi M, Chiba T, Kanai F, Yokosuka O, Yamaguchi T. Natural history of postvascular-phase iso-enhanced lesions on the sonogram in chronic liver diseases. J Gastroenterol Hepatol 2014;29:165-72. [PMID: 24224484 DOI: 10.1111/jgh.12449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
288 Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-65. [PMID: 17953709 DOI: 10.1111/j.1349-7006.2007.00648.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 71] [Article Influence: 0.9] [Reference Citation Analysis]
289 Sarin SK, Kumar M, Garg S, Hissar S, Pandey C, Sharma BC. High dose vitamin K3 infusion in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2006;21:1478-82. [PMID: 16911696 DOI: 10.1111/j.1440-1746.2006.04383.x] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
290 Chen T, Chang T, Huang P, Tsai M, Lin L, Liu C, Ho K, Siauw C, Chao P, Tung J. Management and patient survival in hepatocellular carcinoma: Does the physician's level of experience matter? Journal of Gastroenterology and Hepatology 2008;23:e179-88. [DOI: 10.1111/j.1440-1746.2008.05341.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
291 Guarino M, Di Costanzo GG, Gallotta A, Tortora R, Paneghetti L, Auriemma F, Tuccillo C, Fassina G, Caporaso N, Morisco F. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. Scand J Clin Lab Invest 2017;77:448-53. [PMID: 28609160 DOI: 10.1080/00365513.2017.1336569] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
292 Wu K, Ding J, Chen C, Sun W, Ning BF, Wen W, Huang L, Han T, Yang W, Wang C, Li Z, Wu MC, Feng GS, Xie WF, Wang HY. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology. 2012;56:2255-2267. [PMID: 22898879 DOI: 10.1002/hep.26007] [Cited by in Crossref: 149] [Cited by in F6Publishing: 128] [Article Influence: 18.6] [Reference Citation Analysis]
293 Roumanis PS, Bhargava P, Kimia Aubin G, Choi JI, Demirjian AN, Thayer DA, Lall C. Atypical magnetic resonance imaging findings in hepatocellular carcinoma. Curr Probl Diagn Radiol 2015;44:237-45. [PMID: 25823550 DOI: 10.1067/j.cpradiol.2014.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
294 Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer. 2008;113:995-1003. [PMID: 18615601 DOI: 10.1002/cncr.23684] [Cited by in Crossref: 109] [Cited by in F6Publishing: 92] [Article Influence: 8.4] [Reference Citation Analysis]
295 Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 2007;45:1169-1179. [PMID: 17635075 DOI: 10.1515/cclm.2007.262] [Cited by in Crossref: 58] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
296 Forns X, Sánchez Tapias JM, Parés A, Llovet JM, Bruix J, Rodés J. Expected developments in hepatology. Best Practice & Research Clinical Gastroenterology 2002;16:957-70. [DOI: 10.1053/bega.2002.0341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
297 Seki A, Hori S, Kobayashi K, Narumiya S. Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience. Cardiovasc Intervent Radiol. 2011;34:557-565. [PMID: 20821211 DOI: 10.1007/s00270-010-9975-y] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
298 Cho-Rok J, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, Choi JY, Im DS. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology. 2006;43:1042-1052. [PMID: 16628636 DOI: 10.1002/hep.21137] [Cited by in Crossref: 83] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
299 Kohi MP, Fidelman N, Naeger DM, LaBerge JM, Gordon RL, Kerlan RK. Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? J Vasc Interv Radiol. 2013;24:68-73. [PMID: 23176968 DOI: 10.1016/j.jvir.2012.08.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
300 Li F, Guo Z, Zhang Y, Wang H, Zhang X, Si T, Yu H, Qi L. Postoperative adjuvant arterial chemoembolization improves the survival of hepatitis B virus-related hepatocellular carcinoma: a retrospective control study. Ir J Med Sci 2015;184:753-9. [PMID: 24972992 DOI: 10.1007/s11845-014-1164-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
301 Li Y, Chen X, Lu H. Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion. Oncol Res 2016;24:511-9. [PMID: 28281971 DOI: 10.3727/096504016X14719078133483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
302 Zhang X, Qi X, Meng B, Liu C, Yu L, Wang B, Lv Y. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: Comparison of five staging systems. European Journal of Surgical Oncology (EJSO) 2010;36:718-24. [DOI: 10.1016/j.ejso.2010.05.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
303 Cherqui D, Laurent A, Tayar C, Chang S, Van Nhieu JT, Loriau J, Karoui M, Duvoux C, Dhumeaux D, Fagniez PL. Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives. Ann Surg 2006;243:499-506. [PMID: 16552201 DOI: 10.1097/01.sla.0000206017.29651.99] [Cited by in Crossref: 229] [Cited by in F6Publishing: 200] [Article Influence: 15.3] [Reference Citation Analysis]
304 Cucchetti A, Piscaglia F, Grigioni AD, Ravaioli M, Cescon M, Zanello M, Grazi GL, Golfieri R, Grigioni WF, Pinna AD. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol. 2010;52:880-888. [PMID: 20409605 DOI: 10.1016/j.jhep.2009.12.037] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 10.0] [Reference Citation Analysis]
305 Adán Merino L, Olveira Martín A, Pérez Robledo JP, Prieto I, Gea Rodriguez F, Castillo Grau P, Martín Arranz E, Alonso Gamarra E, Mora Sanz P. [Percutaneous radiofrequency ablation with artificial ascites for hepatocellular carcinoma adjacent to the diaphragm]. Gastroenterol Hepatol 2010;33:709-15. [PMID: 21059478 DOI: 10.1016/j.gastrohep.2010.09.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
306 Bartlett A, Heaton N. Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. World J Gastroenterol. 2008;14:4445-4453. [PMID: 18680222 DOI: 10.3748/wjg.14.4445] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
307 Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer. 2008;44:528-538. [PMID: 18242076 DOI: 10.1016/j.ejca.2008.01.004] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 4.6] [Reference Citation Analysis]
308 Sun T, Han J, Liu S, Wang X, Wang ZY, Xie Z. Tailor-Made Semiconducting Polymers for Second Near-Infrared Photothermal Therapy of Orthotopic Liver Cancer. ACS Nano 2019;13:7345-54. [PMID: 31188558 DOI: 10.1021/acsnano.9b03910] [Cited by in Crossref: 58] [Cited by in F6Publishing: 39] [Article Influence: 29.0] [Reference Citation Analysis]
309 Tong H, Li X, Zhang CL, Gao JH, Wen SL, Huang ZY, Wen FQ, Fu P, Tang CW. Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts. J Dig Dis 2013;14:29-37. [PMID: 23134145 DOI: 10.1111/1751-2980.12001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
310 de Sio I, Iadevaia MD, Vitale LM, Niosi M, Del Prete A, de Sio C, Romano L, Funaro A, Meucci R, Federico A, Loguercio C, Romano M. Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A single-center retrospective study. United European Gastroenterol J 2014;2:279-87. [PMID: 25083285 DOI: 10.1177/2050640614538964] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
311 Ueno M, Hayami S, Kawai M, Hirono S, Okada KI, Miyazawa M, Kitahata Y, Miyamoto A, Suzaki N, Nakamura M, Yamaue H. Prognostic impact of adjuvant chemolipiodolization and treatment frequency on patients with hepatocellular carcinoma after hepatectomy: Prospective study with historical control group. Surg Oncol 2021;36:99-105. [PMID: 33321415 DOI: 10.1016/j.suronc.2020.12.002] [Reference Citation Analysis]
312 Liu Z, Zhou Y, Zhang P, Qin H. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech. 2010;20:130-140. [PMID: 20551807 DOI: 10.1097/sle.0b013e3181d823df] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
313 Wang Z, Yang G, Nie P, Fu J, Wang X, Liu D. Dynamical observation on biological progression of VX2 liver tumors to identify the optimal time for intervention in animal models. PLoS One 2013;8:e74327. [PMID: 23977399 DOI: 10.1371/journal.pone.0074327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
314 Xu LL, Zhang M, Yi PS, Zheng XB, Feng L, Lan C, Tang JW, Ren SS, Xu MQ. Hepatic resection combined with radiofrequency ablation versus hepatic resection alone for multifocal hepatocellular carcinomas: A meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2017;37:974-980. [PMID: 29270762 DOI: 10.1007/s11596-017-1836-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
315 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2003;19:243-9. [DOI: 10.1097/00001574-200305000-00007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
316 Ma XL, Jiang M, Zhao Y, Wang BL, Shen MN, Zhou Y, Zhang CY, Sun YF, Chen JW, Hu B, Gong ZJ, Zhang X, Cao Y, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2018;25:1686-94. [PMID: 29626309 DOI: 10.1245/s10434-018-6402-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
317 He X, Huang Z, Liu P, Li Q, Wang M, Qiu M, Xiong Z, Yang S. Apatinib Inhibits the Invasion and Metastasis of Liver Cancer Cells by Downregulating MMP-Related Proteins via Regulation of the NF-κB Signaling Pathway. Biomed Res Int 2020;2020:3126182. [PMID: 32685465 DOI: 10.1155/2020/3126182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
318 Martin RCG. Irreversible Electroporation: a Novel Option for Treatment of Hepatic Metastases. Curr Colorectal Cancer Rep 2013;9:191-7. [DOI: 10.1007/s11888-013-0166-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
319 Jin YJ, Nah SY, Lee JW, Lee JI, Jeong S, Lee DH, Kim YS, Cho SG, Jeon YS. Utility of adding Primovist magnetic resonance imaging to analysis of hepatocellular carcinoma by liver dynamic computed tomography. Clin Gastroenterol Hepatol 2013;11:187-92. [PMID: 23142203 DOI: 10.1016/j.cgh.2012.11.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
320 Shan SG, Gao YT, Xu YJ, Huang Y, Zhang Q, Zhai DK, Li JB, Wang FM, Jing X, Du Z, Wang YJ. Gradually increased Golgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients. Hepatol Res. 2013;43:1199-1210. [PMID: 23607749 DOI: 10.1111/hepr.12078] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
321 Huo TI, Wu JC, Hsia CY, Chau GY, Lui WY, Huang YH, Lee PC, Chang FY, Lee SD. Hepatitis C virus infection is a risk factor for tumor recurrence after resection of small hepatocellular carcinomas. World J Surg 2004;28:787-91. [PMID: 15457359 DOI: 10.1007/s00268-004-7320-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
322 Yimingjiang M, Tuergan T, Chen X, Wen H, Shao Y, Zhang R, Aihaiti K, Xue J, Aji T, Zhang W. Comparative Analysis of Immunoactivation by Nanosecond Pulsed Electric Fields and PD-1 Blockade in Murine Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2020;2020:9582731. [PMID: 32802733 DOI: 10.1155/2020/9582731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
323 Murata S, Tajima H, Nakazawa K, Onozawa S, Kumita S, Nomura K. Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts. Eur Radiol. 2009;19:2016-2023. [PMID: 19238387 DOI: 10.1007/s00330-009-1349-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
324 Real M, Bianchi L, Vilana R, Burrel M, Rimola J. Tratamiento percutáneo e intraarterial del carcinoma hepatocelular. Radiología 2010;52:399-413. [DOI: 10.1016/j.rx.2010.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
325 Shen Z, Wong OG, Yao RY, Liang J, Kung HF, Lin MC. A novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma. Cancer Lett. 2008;272:268-276. [PMID: 18722051 DOI: 10.1016/j.canlet.2008.03.064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
326 Lee T, Tai D, Cheng C, Sun C, Lin C, Sheu M, Lee W, Peng C, Wang AH, Tsai S. Enhanced nuclear factor-kappa B-associated Wnt-1 expression in hepatitis B- and C-related hepatocarcinogenesis: identification by functional proteomics. J Biomed Sci 2006;13:27-39. [DOI: 10.1007/s11373-005-9030-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
327 Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 2015;141:861-76. [DOI: 10.1007/s00432-014-1806-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 8.4] [Reference Citation Analysis]
328 Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol. 2007;5:1100-1108. [PMID: 17627902 DOI: 10.1016/j.cgh.2007.04.021] [Cited by in Crossref: 185] [Cited by in F6Publishing: 162] [Article Influence: 13.2] [Reference Citation Analysis]
329 Fuster J, Charco R, Llovet JM, Bruix J, García-Valdecasas JC. Liver transplantation in hepatocellular carcinoma. Transpl Int. 2005;18:278-282. [PMID: 15730486 DOI: 10.1111/j.1432-2277.2004.00046.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
330 Tsai Y, Hsu C, Huang Y, Su C, Lin H, Lee R, Chiang J, Huo T, Lee S. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int 2011;5:975-84. [DOI: 10.1007/s12072-011-9276-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
331 Yang X, Wang D, Dong W, Song Z, Dou K. Expression and modulation of Na(+) /H(+) exchanger 1 gene in hepatocellular carcinoma: A potential therapeutic target. J Gastroenterol Hepatol. 2011;26:364-370. [PMID: 21261728 DOI: 10.1111/j.1440-1746.2010.06382.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
332 Marasco G, Poggioli F, Colecchia A, Cabibbo G, Pelizzaro F, Giannini EG, Marinelli S, Rapaccini GL, Caturelli E, Di Marco M, Biasini E, Marra F, Morisco F, Foschi FG, Zoli M, Gasbarrini A, Svegliati Baroni G, Masotto A, Sacco R, Raimondo G, Azzaroli F, Mega A, Vidili G, Brunetto MR, Nardone G, Alemanni LV, Dajti E, Ravaioli F, Festi D, Trevisani F, Italian Liver Cancer Ita Li Ca Group OBOT. A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. Cancers (Basel) 2021;13:2677. [PMID: 34072309 DOI: 10.3390/cancers13112677] [Reference Citation Analysis]
333 Itoh S, Shirabe K, Matsumoto Y, Yoshiya S, Muto J, Harimoto N, Yamashita Y, Ikegami T, Yoshizumi T, Nishie A, Maehara Y. Effect of Body Composition on Outcomes after Hepatic Resection for Hepatocellular Carcinoma. Ann Surg Oncol 2014;21:3063-8. [DOI: 10.1245/s10434-014-3686-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 10.7] [Reference Citation Analysis]
334 Arita J, Sugawara Y, Hashimoto T, Kaneko J, Kokudo N, Makuuchi M, Maruo Y. Liver resection in patients with Gilbert's syndrome. Surgery 2003;134:835-7. [DOI: 10.1016/s0039-6060(03)00320-9] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
335 Schwartz M, Roayaie S, Uva P. Treatment of HCC in patients awaiting liver transplantation. Am J Transplant. 2007;7:1875-1881. [PMID: 17532747 DOI: 10.1111/j.1600-6143.2007.01863.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
336 Santambrogio R, Opocher E, Zuin M, Selmi C, Bertolini E, Costa M, Conti M, Montorsi M. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class a liver cirrhosis. Ann Surg Oncol. 2009;16:3289-3298. [PMID: 19727960 DOI: 10.1245/s10434-009-0678-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
337 Zheng YB, Meng QW, Zhao W, Liu B, Huang JW, He X, Li Y, Hu BS, Lu LG. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Med Oncol. 2014;31:843. [PMID: 24442426 DOI: 10.1007/s12032-014-0843-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
338 Ince V, Ara C, Yilmaz S. Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1118-21. [PMID: 32860615 DOI: 10.1007/s12029-020-00484-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
339 Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. Journal of Hepatology 2012;56:886-92. [DOI: 10.1016/j.jhep.2011.10.021] [Cited by in Crossref: 112] [Cited by in F6Publishing: 94] [Article Influence: 12.4] [Reference Citation Analysis]
340 Burra P, Lucey MR. Liver transplantation in alcoholic patients. Transpl Int. 2005;18:491-498. [PMID: 15819795 DOI: 10.1111/j.1432-2277.2005.00079.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
341 Spangenberg HC, Thimme R, Blum HE. Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:425-33. [PMID: 19072390 DOI: 10.1586/17474124.2.3.425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
342 Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or benefit? Transl Gastroenterol Hepatol. 2017;2:106. [PMID: 29354763 DOI: 10.21037/tgh.2017.11.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
343 Marsh JW, Geller DA, Finkelstein SD, Donaldson JB, Dvorchik I. Role of liver transplantation for hepatobiliary malignant disorders. Lancet Oncol. 2004;5:480-488. [PMID: 15288237 DOI: 10.1016/S1470-2045(04)01527-X] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
344 Lu LH, Mei J, Kan A, Ling YH, Li SH, Wei W, Chen MS, Zhang YF, Guo RP. Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation. Cancer Med. 2020;9:2997-3005. [PMID: 32108433 DOI: 10.1002/cam4.2951] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
345 Iezzi R, Pompili M, Rinninella E, Annicchiarico E, Garcovich M, Cerrito L, Ponziani F, De Gaetano A, Siciliano M, Basso M, Zocco MA, Rapaccini G, Posa A, Carchesio F, Biolato M, Giuliante F, Gasbarrini A, Manfredi R; HepatoCatt Study Group. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol. 2019;29:1285-1292. [PMID: 30171360 DOI: 10.1007/s00330-018-5692-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
346 Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev. 2006;32:28-44. [PMID: 16337744 DOI: 10.1016/j.ctrv.2005.10.004] [Cited by in Crossref: 88] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
347 Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH, DeMatteo RP. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003;238:315-21; discussion 321-3. [PMID: 14501497 DOI: 10.1097/01.sla.0000086548.84705.ef] [Cited by in Crossref: 106] [Cited by in F6Publishing: 131] [Article Influence: 5.9] [Reference Citation Analysis]
348 Thng Y, Tan JK, Shridhar IG, Chang SK, Madhavan K, Kow AW. Outcomes of resection of giant hepatocellular carcinoma in a tertiary institution: does size matter? HPB (Oxford) 2015;17:988-93. [PMID: 26334002 DOI: 10.1111/hpb.12479] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
349 Furuse J. Growth factors as therapeutic targets in HCC. Crit Rev Oncol Hematol 2008;67:8-15. [PMID: 18434184 DOI: 10.1016/j.critrevonc.2008.02.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
350 Motola-kuba D, Zamora-valdés D, Uribe M, Méndez-sánchez N. Hepatocellular carcinoma. An overview. Annals of Hepatology 2006;5:16-24. [DOI: 10.1016/s1665-2681(19)32034-4] [Cited by in Crossref: 88] [Article Influence: 5.9] [Reference Citation Analysis]
351 Zheng YB, Huang JW, Zhan MX, Zhao W, Liu B, He X, Li Y, Hu BS, Lu LG. Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma. Tumour Biol 2014;35:11473-81. [PMID: 25123269 DOI: 10.1007/s13277-014-2478-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
352 Chen L, Yu CX, Zhong BY, Zhu HD, Jin ZC, Zhu GY, Zhang Q, Ni CF, Teng GJ. Development of TACE Refractoriness Scores in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:615133. [PMID: 33981722 DOI: 10.3389/fmolb.2021.615133] [Reference Citation Analysis]
353 Park HK, Lee SS, Im CB, Im C, Cha RR, Kim WS, Cho HC, Lee JM, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. BMC Cancer 2019;19:822. [PMID: 31429755 DOI: 10.1186/s12885-019-6040-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
354 Lyu Z, Ma M, Xu Y, Wang X, Zhu Y, Ren W, Li T. Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma. Int J Clin Oncol 2020;25:1334-45. [PMID: 32347431 DOI: 10.1007/s10147-020-01675-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, Lee SJ, Lim YS. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. Radiology 2019;292:390-7. [PMID: 31210614 DOI: 10.1148/radiol.2019190035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
356 Jung YK, Jung CH, Seo YS, Kim JH, Kim TH, Yoo YJ, Kang SH, Yim SY, Suh SJ, An H, Yim HJ, Yeon JE, Byun KS, Um SH. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. J Gastroenterol Hepatol 2016;31:467-74. [PMID: 26332049 DOI: 10.1111/jgh.13152] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
357 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z, Lou M, Lv J. Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med. 2012;3:171-180. [PMID: 22969864 DOI: 10.3892/etm.2011.398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
358 Gaiani S, Celli N, Cecilioni L, Piscaglia F, Bolondi L. Percutaneous treatment of hepatocellular carcinoma: REVIEW: PERCUTANEOUS TREATMENT OF HEPATOCELLULAR CARCINOMA. Alimentary Pharmacology & Therapeutics 2003;17:103-10. [DOI: 10.1046/j.1365-2036.17.s2.21.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
359 Harimoto N, Yoshizumi T, Fujimoto Y, Motomura T, Mano Y, Toshima T, Itoh S, Harada N, Ikegami T, Uchiyama H, Soejima Y, Maehara Y. Surgery for Hepatocellular Carcinoma in Patients with Child–Pugh B Cirrhosis: Hepatic Resection Versus Living Donor Liver Transplantation. World J Surg 2018;42:2606-16. [DOI: 10.1007/s00268-018-4493-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
360 Ho CM, Lee PH, Chen CL, Ho MC, Wu YM, Hu RH. Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria. Ann Surg Oncol. 2012;19:826-833. [PMID: 21879276 DOI: 10.1245/s10434-011-1975-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
361 Yang X, Wang D, Dong W, Song Z, Dou K. Suppression of Na+/H + exchanger 1 by RNA interference or amiloride inhibits human hepatoma cell line SMMC-7721 cell invasion. Med Oncol. 2011;28:385-390. [PMID: 20151228 DOI: 10.1007/s12032-010-9447-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
362 Chapman WC, Klintmalm G, Hemming A, Vachharajani N, Majella Doyle MB, DeMatteo R, Zaydfudim V, Chung H, Cavaness K, Goldstein R. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg. 2015;220:628-637. [PMID: 25728142 DOI: 10.1016/j.jamcollsurg.2014.12.030] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 8.5] [Reference Citation Analysis]
363 Zhang CH, Xu GL, Jia WD, Ge YS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer. 2009;124:2982-2988. [PMID: 19296539 DOI: 10.1002/ijc.24311] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
364 Sherman M. Modern Approach to Hepatocellular Carcinoma. Curr Gastroenterol Rep 2011;13:49-55. [DOI: 10.1007/s11894-010-0163-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
365 Bannerman D, Wan W. Multifunctional microbeads for drug delivery in TACE. Expert Opinion on Drug Delivery 2016;13:1289-300. [DOI: 10.1080/17425247.2016.1192122] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
366 Lee SJ, Cho EH, Kim R, Kim YH, Lim CS, Kim SB. Hepatectomy, combined with intraoperative radiofrequency ablation in patients with multiple hepatocellular carcinomas. Korean J Hepatobiliary Pancreat Surg 2015;19:98-102. [PMID: 26379730 DOI: 10.14701/kjhbps.2015.19.3.98] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
367 Kow AWC. Transplantation vs liver resection in patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2019;4:33. [PMID: 31231700 DOI: 10.21037/tgh.2019.05.06] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
368 Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008;8:200. [PMID: 18638391 DOI: 10.1186/1471-2407-8-200] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
369 Dong Y, Wang W, Gan Y, Huang B, Ding H. Radiofrequency ablation guided by contrast-enhanced ultrasound for hepatic malignancies: Preliminary results. Clinical Radiology 2014;69:1129-35. [DOI: 10.1016/j.crad.2014.06.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
370 Laurent A, Tayar C, Andréoletti M, Lauzet JY, Merle JC, Cherqui D. Laparoscopic liver resection facilitates salvage liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2009;16:310-4. [PMID: 19280110 DOI: 10.1007/s00534-009-0063-0] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 8.3] [Reference Citation Analysis]
371 Zhao C, Fan L, Qi F, Ou S, Yu L, Yi X, Ni B, Zheng Z, Lu J, Zhang C, Chen C, Lu X, Cheng L, Hu T, Ma Y. Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Anticancer Drugs 2016;27:689-94. [PMID: 27145327 DOI: 10.1097/CAD.0000000000000371] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
372 Capussotti L, Muratore A, Massucco P, Ferrero A, Polastri R, Bouzari H. Major liver resections for hepatocellular carcinoma on cirrhosis: early and long-term outcomes. Liver Transpl. 2004;10:S64-S68. [PMID: 14762842 DOI: 10.1002/lt.20035] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
373 Ribero D, Curley SA, Imamura H, Madoff DC, Nagorney DM, Ng KK, Donadon M, Vilgrain V, Torzilli G, Roh M, Vauthey J. Selection for Resection of Hepatocellular Carcinoma and Surgical Strategy: Indications for Resection, Evaluation of Liver Function, Portal Vein Embolization, and Resection. Ann Surg Oncol 2008;15:986-92. [DOI: 10.1245/s10434-007-9731-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
374 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362:1907-17. [DOI: 10.1016/s0140-6736(03)14964-1] [Cited by in Crossref: 3076] [Cited by in F6Publishing: 1215] [Article Influence: 170.9] [Reference Citation Analysis]
375 Oh YJ, Park YM, Kim BH, Kim MJ, Cho JH, Cha CW, Park SJ, Yeon JW. A case of hepatocellular carcinoma with pulmonary metastases treated successfully with a combination of repeated hepatic arterial infusion epirubicin and Cisplatin chemotherapy and systemic low-dose infusion of 5-Fluorouracil. Gut Liver 2009;3:343-8. [PMID: 20431774 DOI: 10.5009/gnl.2009.3.4.343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
376 Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl. 2006;12:1028-1036. [PMID: 16799950 DOI: 10.1002/lt.20833] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
377 Koido S, Homma S, Hara E, Mitsunaga M, Namiki Y, Takahara A, Nagasaki E, Komita H, Sagawa Y, Ohkusa T, Fujise K, Gong J, Tajiri H. In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. J Transl Med 2008;6:51. [PMID: 18793383 DOI: 10.1186/1479-5876-6-51] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
378 Tsoulfas G, Kawai T, Elias N, Ko SC, Agorastou P, Cosimi AB, Hertl M. Long-term experience with liver transplantation for hepatocellular carcinoma. J Gastroenterol 2011;46:249-56. [PMID: 20711612 DOI: 10.1007/s00535-010-0302-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
379 Fortune BE, Umman V, Gilliland T, Emre S. Liver transplantation for hepatocellular carcinoma: a surgical perspective. J Clin Gastroenterol 2013;47 Suppl:S37-42. [PMID: 23632344 DOI: 10.1097/MCG.0b013e318286ff8e] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
380 Yoon YS, Han HS, Cho JY, Yoon CJ, Kim JH. Laparoscopic approach for treatment of multiple hepatocellular carcinomas. Surg Endosc. 2012;26:3133-3140. [PMID: 22538699 DOI: 10.1007/s00464-012-2304-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
381 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3142] [Article Influence: 404.7] [Reference Citation Analysis]
382 Feng M, Ben-Josef E. Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol. 2011;21:271-277. [PMID: 21939856 DOI: 10.1016/j.semradonc.2011.05.002] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 7.4] [Reference Citation Analysis]
383 Kondo T, Maruyama H, Sekimoto T, Shimada T, Takahashi M, Okugawa H, Yokosuka O. Impact of portal hemodynamics on Doppler ultrasonography for predicting decompensation and long-term outcomes in patients with cirrhosis. Scand J Gastroenterol. 2016;51:236-244. [PMID: 26357874 DOI: 10.3109/00365521.2015.1081275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
384 Khalaf N, Ying J, Mittal S, Temple S, Kanwal F, Davila J, El-Serag HB. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clin Gastroenterol Hepatol 2017;15:273-281.e1. [PMID: 27521507 DOI: 10.1016/j.cgh.2016.07.033] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 11.8] [Reference Citation Analysis]
385 Rubio C, Morera R, Hernando O, Leroy T, Lartigau SE. Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors. Rep Pract Oncol Radiother 2013;18:387-96. [PMID: 24416584 DOI: 10.1016/j.rpor.2013.09.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
386 Zheng FQ, Xu Y, Yang RJ, Wu B, Tan XH, Qin YD, Zhang QW. Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models. Acta Pharmacol Sin 2009;30:617-27. [PMID: 19363518 DOI: 10.1038/aps.2009.33] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
387 Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastro 2004;7:431-41. [DOI: 10.1007/s11938-004-0002-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
388 Kohli A, Murphy AA, Agarwal C, Shivakumar B, Kottilil S, Polis MA, Subramanian GM, Midha V, Goyal O, Desai S, Sood A, Shah S. HCC surveillance results in earlier HCC detection: results from an Indian cohort. Springerplus 2014;3:610. [PMID: 25392781 DOI: 10.1186/2193-1801-3-610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
389 Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. Journal of Hepatology 2003;39:1076-84. [DOI: 10.1016/s0168-8278(03)00349-0] [Cited by in Crossref: 135] [Cited by in F6Publishing: 47] [Article Influence: 7.5] [Reference Citation Analysis]
390 Zhao R, Li T, Zheng G, Jiang K, Fan L, Shao J. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. Biomaterials 2017;143:1-16. [DOI: 10.1016/j.biomaterials.2017.07.030] [Cited by in Crossref: 86] [Cited by in F6Publishing: 65] [Article Influence: 21.5] [Reference Citation Analysis]
391 Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, Guglielmi A. Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation. World J Gastroenterol. 2004;10:1137-1140. [PMID: 15069713 DOI: 10.3748/wjg.v10.i8.1137] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 83] [Article Influence: 5.7] [Reference Citation Analysis]
392 Cai MY, Wang FW, Li CP, Yan LX, Chen JW, Luo RZ, Yun JP, Zeng YX, Xie D. Prognostic factors affecting postoperative survival of patients with solitary small hepatocellular carcinoma. Chin J Cancer 2016;35:80. [PMID: 27527497 DOI: 10.1186/s40880-016-0143-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
393 Liu X, Wan X, Li Z, Lin C, Zhan Y, Lu X. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med. 2011;49:1311-1316. [PMID: 21663469 DOI: 10.1515/cclm.2011.640] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
394 Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology 2015;149:119-29. [PMID: 25836985 DOI: 10.1053/j.gastro.2015.03.044] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
395 Zimmermann M, Weiland T, Bitzer M, Lauer UM. Preclinical testing of virotherapeutics for primary and secondary tumors of the liver. Methods Mol Biol 2012;806:121-36. [PMID: 22057449 DOI: 10.1007/978-1-61779-367-7_9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
396 Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol. 2011;54:497-505. [PMID: 21112656 DOI: 10.1016/j.jhep.2010.07.044] [Cited by in Crossref: 161] [Cited by in F6Publishing: 163] [Article Influence: 14.6] [Reference Citation Analysis]
397 Yao FY, Roberts JP. Applying expanded criteria to liver transplantation for hepatocellular carcinoma: Too much too soon, or is now the time? Liver Transpl 2004;10:919-21. [DOI: 10.1002/lt.20190] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
398 Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y, Terae S, Shirato H. Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection. Jpn J Radiol 2009;27:185-93. [PMID: 19499310 DOI: 10.1007/s11604-009-0317-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
399 Wada H, Nagano H, Yamamoto H, Noda T, Murakami M, Kobayashi S, Marubashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. BMC Cancer 2009;9:361. [PMID: 19821965 DOI: 10.1186/1471-2407-9-361] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
400 Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol. 2002;35:S138-S142. [PMID: 12394217 DOI: 10.1097/00004836-200211002-00010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
401 Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, Yamamoto K. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer. 2008;98:1161-1165. [PMID: 18349849 DOI: 10.1038/sj.bjc.6604282] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
402 Chung WS, Lee KH, Park MS, Lee YJ, Kwon J, Baek SE, Kim MJ. Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study. AJR Am J Roentgenol. 2012;199:349-359. [PMID: 22826396 DOI: 10.2214/ajr.11.7563] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
403 Ronzoni A, Artioli D, Scardina R, Battistig L, Minola E, Sironi S, Vanzulli A. Role of MDCT in the diagnosis of hepatocellular carcinoma in patients with cirrhosis undergoing orthotopic liver transplantation. AJR Am J Roentgenol 2007;189:792-8. [PMID: 17885047 DOI: 10.2214/AJR.07.2040] [Cited by in Crossref: 31] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
404 Yoo D, Kim KM, Jin Y, Shim JH, Ko G, Yoon H, Sung K, Lee J, Kang Y, Lim Y, Lee HC, Chung Y, Lee YS, Suh DJ. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?: Efficacy of TACE in HCC with metastasis. Journal of Gastroenterology and Hepatology 2011;26:145-54. [DOI: 10.1111/j.1440-1746.2010.06341.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
405 Chacko S, Samanta S. "Hepatocellular carcinoma: A life-threatening disease". Biomed Pharmacother. 2016;84:1679-1688. [PMID: 27823920 DOI: 10.1016/j.biopha.2016.10.078] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
406 Takayasu K, Muramatsu Y, Mizuguchi Y, Moriyama N, Okusaka T. Multiple non-tumorous arterioportal shunts due to chronic liver disease mimicking hepatocellular carcinoma: outcomes and the associated elevation of alpha-fetoprotein. J Gastroenterol Hepatol. 2006;21:288-294. [PMID: 16460488 DOI: 10.1111/j.1440-1746.2006.04170.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
407 Azab M, Zaki S, El-Shetey AG, Abdel-Moty MF, Alnoomani NM, Gomaa AA, Abdel-Fatah S, Mohiy S, Atia F. Radiofrequency ablation combined with percutaneous ethanol injection in patients with hepatocellular carcinoma. Arab J Gastroenterol. 2011;12:113-118. [PMID: 22055587 DOI: 10.1016/j.ajg.2011.07.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
408 Li F, Guo Z, Lizée G, Yu H, Wang H, Si T. Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients. Clin Chem Lab Med. 2014;52:1357-1365. [PMID: 24646790 DOI: 10.1515/cclm-2013-0878] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
409 Sonnenberg A. Decision analysis in clinical gastroenterology. Am J Gastroenterol 2004;99:163-9. [PMID: 14687159 DOI: 10.1111/j.1572-0241.2004.04011.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
410 Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, Kianmanesh R, Ng IO, Curley SA, Yamaoka Y. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137:403-410. [PMID: 15800485 DOI: 10.1016/j.surg.2004.12.012] [Cited by in Crossref: 161] [Cited by in F6Publishing: 137] [Article Influence: 10.1] [Reference Citation Analysis]
411 Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, D'amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D'amico DF. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? Journal of Hepatology 2004;40:124-31. [DOI: 10.1016/j.jhep.2003.09.027] [Cited by in Crossref: 133] [Cited by in F6Publishing: 119] [Article Influence: 7.8] [Reference Citation Analysis]
412 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
413 Cammà C, Licata A, Cabibbo G, Latteri F, Craxì A. Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother. 2005;6:399-408. [PMID: 15794731 DOI: 10.1517/14656566.6.3.399] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
414 Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:1437-1444. [PMID: 19486255 DOI: 10.1111/j.1440-1746.2009.05863.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
415 Müller C, Schöniger-hekele M, Schernthaner R, Renner B, Peck-radosavljevic M, Brichta A, Wrba F, Posch M, Bauer P, Ferenci P, Gangl A. Percutaneous ethanol instillation therapy for hepatocellular carcinoma – a randomized controlled trial. Wien Klin Wochenschr 2008;120:608-18. [DOI: 10.1007/s00508-008-1086-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
416 Bonekamp S, Corona-Villalobos CP, Kamel IR. Oncologic applications of diffusion-weighted MRI in the body. J Magn Reson Imaging. 2012;35:257-279. [PMID: 22271274 DOI: 10.1002/jmri.22786] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
417 Letreut Y, Hardwigsen J, Ananian P, Saisse J, Gregoire E, Richa H, Campan P. Resection of Hepatocellular Carcinoma with Tumor Thrombus in the Major Vasculature. A European Case-Control Series. Journal of Gastrointestinal Surgery 2006;10:855-62. [DOI: 10.1016/j.gassur.2005.12.011] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 5.9] [Reference Citation Analysis]
418 Janvilisri T, Leelawat K, Roytrakul S, Paemanee A, Tohtong R. Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach. Dis Markers. 2015;2015:105358. [PMID: 26060332 DOI: 10.1155/2015/105358] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
419 Kothary N, Weintraub JL, Susman J, Rundback JH. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol. 2007;18:1517-1526; quiz 1527. [PMID: 18057286 DOI: 10.1016/j.jvir.2007.07.035] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
420 Choti MA. Transplantation versus resection for hepatocellular carcinoma in the mild cirrhotic: framing the debate. J Gastrointest Surg. 2009;13:1021-1022. [PMID: 19333661 DOI: 10.1007/s11605-009-0868-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
421 Guo Y, Zhao J, Bi J, Wu Q, Wang X, Lai Q. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J Hematol Oncol 2012;5:37. [PMID: 22760167 DOI: 10.1186/1756-8722-5-37] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
422 Todo S, Furukawa H; Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004;240:451-9; discussion 459-61. [PMID: 15319716 DOI: 10.1097/01.sla.0000137129.98894.42] [Cited by in Crossref: 309] [Cited by in F6Publishing: 254] [Article Influence: 18.2] [Reference Citation Analysis]
423 Wang J, Li H, Xia C, Yang X, Dai B, Tao K, Dou K. Downregulation of CENPK suppresses hepatocellular carcinoma malignant progression through regulating YAP1. Onco Targets Ther 2019;12:869-82. [PMID: 30774374 DOI: 10.2147/OTT.S190061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
424 Li L, Gou C, Li J, Achakzai R, Li X. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C. Hepatobiliary & Pancreatic Diseases International 2016;15:152-7. [DOI: 10.1016/s1499-3872(16)60070-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
425 Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010;52:930-936. [PMID: 20385428 DOI: 10.1016/j.jhep.2009.12.032] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 8.0] [Reference Citation Analysis]
426 Roayaie K, Feng S. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? Liver Transpl. 2007;13:S36-S43. [PMID: 17969067 DOI: 10.1002/lt.21329] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
427 Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet 2002;359:1734-9. [DOI: 10.1016/s0140-6736(02)08649-x] [Cited by in Crossref: 2274] [Cited by in F6Publishing: 774] [Article Influence: 119.7] [Reference Citation Analysis]
428 Nagler A, Ohana M, Shibolet O, Shapira M, Alper R, Vlodavsky I, Pines M, Ilan Y. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. European Journal of Cancer 2004;40:1397-403. [DOI: 10.1016/j.ejca.2003.11.036] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
429 Hsu KF, Chu CH, Chan DC, Yu JC, Shih ML, Hsieh HF, Hsieh TY, Yu CY, Hsieh CB. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. Eur J Radiol. 2012;81:466-471. [PMID: 21376495 DOI: 10.1016/j.ejrad.2010.12.058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
430 Borzio M, Fargion S, Borzio F, Fracanzani AL, Croce AM, Stroffolini T, Oldani S, Cotichini R, Roncalli M. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. Journal of Hepatology 2003;39:208-14. [DOI: 10.1016/s0168-8278(03)00190-9] [Cited by in Crossref: 142] [Cited by in F6Publishing: 31] [Article Influence: 7.9] [Reference Citation Analysis]
431 Nishie A, Goshima S, Haradome H, Hatano E, Imai Y, Kudo M, Matsuda M, Motosugi U, Saitoh S, Yoshimitsu K, Crawford B, Kruger E, Ball G, Honda H. Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan. Clin Ther 2017;39:738-750.e4. [PMID: 28363694 DOI: 10.1016/j.clinthera.2017.03.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
432 Bellavance EC, Lumpkins KM, Mentha G, Marques HP, Capussotti L, Pulitano C, Majno P, Mira P, Rubbia-brandt L, Ferrero A, Aldrighetti L, Cunningham S, Russolillo N, Philosophe B, Barroso E, Pawlik TM. Surgical Management of Early-Stage Hepatocellular Carcinoma: Resection or Transplantation? J Gastrointest Surg 2008;12:1699-708. [DOI: 10.1007/s11605-008-0652-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
433 Maruyama H, Kobayashi K, Kiyono S, Ogasawara S, Ooka Y, Suzuki E, Chiba T, Kato N. Left gastric vein-based noninvasive test for esophageal varices: a same-day comparison of portal hemodynamic assessment with endoscopic appearance. Clin Transl Gastroenterol 2018;9:154. [PMID: 29795388 DOI: 10.1038/s41424-018-0021-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
434 Liu L, Zhang QS, Pan LH, Zhong JH, Qin ZM, Wang YY, Qin HG, Gong WF, Qi LN, Xiang BD, Li LQ. Subclassification of patients with solitary hepatocellular carcinoma based on post-hepatectomy survival: a large retrospective study. Tumour Biol 2016;37:5327-35. [PMID: 26561470 DOI: 10.1007/s13277-015-4387-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
435 Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007;25:310-312. [PMID: 17960065 DOI: 10.1159/000106910] [Cited by in Crossref: 156] [Cited by in F6Publishing: 149] [Article Influence: 11.1] [Reference Citation Analysis]
436 Forner A, Real MI, Varela M, Bruix J. Transarterial chemoembolization for patients with hepatocellular carcinoma. Hepatology Research 2007;37:S230-7. [DOI: 10.1111/j.1872-034x.2007.00190.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
437 Makuuchi M, Sugawara Y. Current status of liver transplantation for hepatocellular carcinoma from living donors. Hepatology Research 2007;37:S277-8. [DOI: 10.1111/j.1872-034x.2007.00197.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
438 Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, Burra P, Fagiuoli S, Farinati F, Rugge M, D'Amico DF. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg. 2004;239:150-159. [PMID: 14745321 DOI: 10.1097/01.sla.0000109146.72827.76] [Cited by in Crossref: 243] [Cited by in F6Publishing: 220] [Article Influence: 14.3] [Reference Citation Analysis]
439 Lee YH, Hsu CY, Chu CW, Liu PH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. Radiofrequency ablation is better than surgical resection in patients with hepatocellular carcinoma within the Milan criteria and preserved liver function: a retrospective study using propensity score analyses. J Clin Gastroenterol. 2015;49:242-249. [PMID: 24714185 DOI: 10.1097/mcg.0000000000000133] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 4.2] [Reference Citation Analysis]
440 Kawasoe H, Eguchi Y, Mizuta T, Yasutake T, Ozaki I, Shimonishi T, Miyazaki K, Tamai T, Kato A, Kudo S, Fujimoto K. Radiofrequency ablation with the real-time virtual sonography system for treating hepatocellular carcinoma difficult to detect by ultrasonography. J Clin Biochem Nutr 2007;40:66-72. [PMID: 18437215 DOI: 10.3164/jcbn.40.66] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
441 Huo TI, Wu JC, Lui WY, Lee PC, Huang YH, Chau GY, Tsay SH, Chang FY, Lee SD. Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. Eur J Gastroenterol Hepatol. 2003;15:1203-1208. [PMID: 14560154 DOI: 10.1097/00042737-200311000-00009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
442 Giannelli G, Azzariti A, Fransvea E, Porcelli L, Antonaci S, Paradiso A. Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells. Br J Cancer 2004;91:1964-9. [PMID: 15545972 DOI: 10.1038/sj.bjc.6602231] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
443 Klein J, Korol R, Lo SS, Chu W, Lock M, Dorth JA, Ellis RJ, Mayr NA, Huang Z, Chung HT. Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma. Future Oncol 2014;10:2227-41. [PMID: 25471036 DOI: 10.2217/fon.14.167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
444 Mathews P, Lee D, Chung YH, Kim JA, Lee JH, Jin YJ, Park W, Lyu H, Jaffee E, Zheng L. Effects of genomic changes in hepatitis B virus on postoperative recurrence and survival in patients with hepatocellular carcinoma. Ann Surg Oncol. 2013;20:1216-1222. [PMID: 23104706 DOI: 10.1245/s10434-012-2706-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
445 Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009;14:95-100. [PMID: 19144678 DOI: 10.1634/theoncologist.2008-0185] [Cited by in Crossref: 127] [Cited by in F6Publishing: 115] [Article Influence: 10.6] [Reference Citation Analysis]
446 Lin LW, Lin XD, He YM, Gao SD, Xue ES. Experimental study on ultrasound-guided intratumoral injection of "Star-99" in treatment of hepatocellular carcinoma of nude mice. World J Gastroenterol 2003;9:701-5. [PMID: 12679914 DOI: 10.3748/wjg.v9.i4.701] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
447 Jin YJ, Cho SG, Lee KY, Kim JM, Lee JW. Association between relative liver enhancement on gadoxetic acid enhanced magnetic resonance images and histologic grade of hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e7580. [PMID: 28746206 DOI: 10.1097/MD.0000000000007580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
448 Zhu Q, Yuan B, Qiao G, Yan J, Li Y, Duan R, Yan Y. Prognostic factors for survival after hepatic resection of early hepatocellular carcinoma in HBV-related cirrhotic patients. Clinics and Research in Hepatology and Gastroenterology 2016;40:418-27. [DOI: 10.1016/j.clinre.2015.12.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
449 Sugino T, Yamaguchi T, Hoshi N, Kusakabe T, Ogura G, Goodison S, Suzuki T. Sinusoidal tumor angiogenesis is a key component in hepatocellular carcinoma metastasis. Clin Exp Metastasis 2008;25:835-41. [PMID: 18712609 DOI: 10.1007/s10585-008-9199-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
450 Burra P, Lucey MR. Liver transplantation for alcoholic liver disease. Clin Liver Dis (Hoboken) 2013;2:92-5. [PMID: 30992833 DOI: 10.1002/cld.204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
451 Lee YH, Hsu CY, Huang YH, Su CW, Lin HC, Hsia CY, Huo TI. α-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma. J Gastrointest Surg 2013;17:730-8. [PMID: 23188220 DOI: 10.1007/s11605-012-2081-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
452 Choi SJ, Kim J, Seo J, Kim HS, Lee JM, Park H. Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization. Eur Radiol 2016;26:225-34. [PMID: 25991485 DOI: 10.1007/s00330-015-3825-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
453 Gou L, Wang W, Tong A, Yao Y, Zhou Y, Yi C, Yang J. Proteomic identification of RhoA as a potential biomarker for proliferation and metastasis in hepatocellular carcinoma. J Mol Med (Berl) 2011;89:817-27. [PMID: 21475975 DOI: 10.1007/s00109-011-0753-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
454 Singh S, Colonna G, Di Bernardo G, Bergantino F, Cammarota M, Castello G, Costantini S. The gene expression profiling of hepatocellular carcinoma by a network analysis approach shows a dominance of intrinsically disordered proteins (IDPs) between hub nodes. Mol Biosyst 2015;11:2933-45. [PMID: 26267014 DOI: 10.1039/c5mb00434a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
455 Vilana R, Llovet JM, Bianchi L, Sanchez M, Pagés M, Sala M, Gilabert R, Nicolau C, Garcia A, Ayuso C. Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound. 2003;31:119-128. [PMID: 12594796 DOI: 10.1002/jcu.10151] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
456 Cohen EI, Field D, Lynskey GE, Kim AY. Technology of irreversible electroporation and review of its clinical data on liver cancers. Expert Rev Med Devices 2018;15:99-106. [PMID: 29307242 DOI: 10.1080/17434440.2018.1425612] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
457 Escarda A, Vaquer P, Bonet L, Miralbés S, Gómez C, Obrador A. [Clivus metastasis from hepatocarcinoma associated with transarterial hepatic chemoembolization]. Gastroenterol Hepatol 2006;29:401-4. [PMID: 16938255 DOI: 10.1157/13091453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
458 Wong JC, Tang G, Wu X, Liang C, Zhang Z, Guo L, Peng Z, Zhang W, Lin X, Wang Z, Mei J, Chen J, Pan S, Zhang N, Liu Y, Zhou M, Feng L, Zhao W, Li S, Zhang C, Zhang M, Rong Y, Jin TG, Zhang X, Ren S, Ji Y, Zhao R, She J, Ren Y, Xu C, Chen D, Cai J, Shan S, Pan D, Ning Z, Lu X, Chen T, He Y, Chen L. Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response. J Med Chem 2012;55:8903-25. [PMID: 23061376 DOI: 10.1021/jm3011838] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
459 Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35:765-774. [PMID: 22648700 DOI: 10.1007/s00270-012-0423-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
460 Cucchetti A, Vivarelli M, Piscaglia F, Nardo B, Montalti R, Grazi GL, Ravaioli M, La Barba G, Cavallari A, Bolondi L. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol. 2005;43:310-316. [PMID: 15970351 DOI: 10.1016/j.jhep.2005.03.014] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
461 Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics 2008;2:453-62. [PMID: 19707376 DOI: 10.2147/btt.s3254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
462 Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, Chen CS. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 2007;46:1119-30. [PMID: 17654699 DOI: 10.1002/hep.21804] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 4.6] [Reference Citation Analysis]
463 Livraghi T, Meloni F, Morabito A, Vettori C. Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl. 2004;10:S98-106. [PMID: 14762848 DOI: 10.1002/lt.20053] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 4.2] [Reference Citation Analysis]
464 Chu HH, Kim JH, Shim JH, Gwon DI, Ko HK, Shin JH, Ko GY, Yoon HK, Kim N. Neutrophil-to-Lymphocyte Ratio as a Biomarker Predicting Overall Survival after Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2830. [PMID: 34204125 DOI: 10.3390/cancers13112830] [Reference Citation Analysis]
465 Wu L, Bartlett A, Plank L, McCall J. Validation of the Hong Kong liver cancer staging system in hepatocellular carcinoma patients treated with curative intent. J Hepatol 2016;64:978-9. [PMID: 26723897 DOI: 10.1016/j.jhep.2015.12.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
466 Bai M, Reynolds NR, Mccorkle R. The promise of clinical interventions for hepatocellular carcinoma from the west to mainland China. Pall Supp Care 2013;11:503-22. [DOI: 10.1017/s1478951512001137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
467 Sun W, Ding J, Wu K, Ning BF, Wen W, Sun HY, Han T, Huang L, Dong LW, Yang W. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells. Hepatology. 2011;54:1259-1272. [PMID: 21735473 DOI: 10.1002/hep.24530] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
468 Young RS, Aldiwani M, Hakeem AR, Nair A, Guthrie A, Wyatt J, Treanor D, Morris-Stiff G, Jones RL, Prasad KR. Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation? HPB (Oxford). 2013;15:418-427. [PMID: 23458127 DOI: 10.1111/hpb.12008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
469 Lencioni R, Crocetti L. A Critical Appraisal of the Literature on Local Ablative Therapies for Hepatocellular Carcinoma. Clinics in Liver Disease 2005;9:301-14. [DOI: 10.1016/j.cld.2004.12.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
470 Liu K, Zhang X, Xu W, Chen J, Yu J, Gamble JR, McCaughan GW. Targeting the vasculature in hepatocellular carcinoma treatment: Starving vs normalizing blood supply.Clin Transl Gastroenterol. 2017;8:e98. [DOI: 10.1038/ctg.2017.28] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 10.5] [Reference Citation Analysis]
471 Zhou S, Shen J, Lin S, Liu X, Xu M, Shi L, Wang X, Cai X. Downregulated expression of DIXDC1 in hepatocellular carcinoma and its correlation with prognosis. Tumor Biol 2016;37:13607-16. [DOI: 10.1007/s13277-016-5213-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
472 Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2015;4:253-262. [PMID: 26734579 DOI: 10.1159/000367743] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 12.2] [Reference Citation Analysis]
473 Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426-432. [PMID: 23269991 DOI: 10.1200/jco.2012.42.9936] [Cited by in Crossref: 260] [Cited by in F6Publishing: 119] [Article Influence: 28.9] [Reference Citation Analysis]
474 Farkas SA, Schlitt HJ. [Operative therapy of hepatocellular carcinoma]. Radiologe. 2014;54:673-678. [PMID: 25047523 DOI: 10.1007/s00117-014-2653-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
475 Bernal P, Raoul JL, Vidmar G, Sereegotov E, Sundram FX, Kumar A, Jeong JM, Pusuwan P, Divgi C, Zanzonico P. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int J Radiat Oncol Biol Phys. 2007;69:1448-1455. [PMID: 17692473 DOI: 10.1016/j.ijrobp.2007.05.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
476 Jiao J, Watt GP, Stevenson HL, Calderone TL, Fisher-Hoch SP, Ye Y, Wu X, Vierling JM, Beretta L. Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors. Hepatol Commun 2018;2:718-31. [PMID: 29881823 DOI: 10.1002/hep4.1187] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
477 Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, Cicorelli A, Tumino E, Federici G, Cioni R. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol. 2012;81:1173-1178. [PMID: 21466931 DOI: 10.1016/j.ejrad.2011.03.046] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
478 Brito AF, Abrantes AM, Tralhão JG, Botelho MF. Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev 2016;10:302. [PMID: 27994769 DOI: 10.4081/oncol.2016.302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
479 Pavel M, Sanchez Cabus S, Crespo G, Ferrer J, Fondevila C, Fuster J, Garcia-valdecasas J. Role of Adult Living Donor Liver Transplantation in the Treatment of Hepatocellular Carcinoma Within and Beyond Milan Criteria: A Comparative Study. Transplantation Proceedings 2018;50:1386-95. [DOI: 10.1016/j.transproceed.2018.02.093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
480 Bass NM. It could have been something they ate – functional food and the treatment of liver cancer. Journal of Hepatology 2002;37:147-50. [DOI: 10.1016/s0168-8278(02)00168-x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
481 Huo T, Wu J, Lui W, Huang Y, Lee P, Chiang J, Chang F, Lee S. Differential Mechanism and Prognostic Impact of Diabetes Mellitus on Patients with Hepatocellular Carcinoma Undergoing Surgical and Nonsurgical Treatment. Am J Gastroenterology 2004;99:1479-87. [DOI: 10.1111/j.1572-0241.2004.30024.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
482 Facciuto ME, Koneru B, Rocca JP, Wolf DC, Kim-Schluger L, Visintainer P, Klein KM, Chun H, Marvin M, Rozenblit G. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation. Ann Surg Oncol. 2008;15:1383-1391. [PMID: 18320284 DOI: 10.1245/s10434-008-9851-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
483 Abbas A, Medvedev S, Shores N, Bazzano L, Dehal A, Hutchings J, Balart L. Epidemiology of metastatic hepatocellular carcinoma, a nationwide perspective. Dig Dis Sci 2014;59:2813-20. [PMID: 24903653 DOI: 10.1007/s10620-014-3229-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
484 Mcnally ME, Martinez A, Khabiri H, Guy G, Michaels AJ, Hanje J, Kirkpatrick R, Bloomston M, Schmidt CR. Inflammatory Markers are Associated with Outcome in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Ann Surg Oncol 2013;20:923-8. [DOI: 10.1245/s10434-012-2639-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
485 Huang GQ, Zhu GQ, Liu YL, Wang LR, Braddock M, Zheng MH, Zhou MT. Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection. Oncotarget. 2016;7:5429-5439. [PMID: 26716411 DOI: 10.18632/oncotarget.6707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
486 Hou YF, Wei YG, Yang JY, Wen TF, Xu MQ, Yan LN, Li B, Chen KF. Microvascular invasion patterns affect survival in hepatocellular carcinoma patients after second hepatectomy. J Surg Res 2016;200:82-90. [PMID: 26259778 DOI: 10.1016/j.jss.2015.06.069] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
487 Cillo U, Vitale A, Navaglia F, Basso D, Montin U, Bassanello M, D'Amico F, Ciarleglio FA, Brolese A, Zanus G, De Pascale V, Plebani M, D'Amico DF. Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World J Gastroenterol 2005;11:6920-5. [PMID: 16437593 DOI: 10.3748/wjg.v11.i44.6920] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
488 Gómez Rodríguez R, Romero Gutiérrez M, González de Frutos C, de Artaza Varasa T, de la Cruz Perez G, Ciampi Dopazo JJ, Lanciego Pérez C, Gómez Moreno AZ. [Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients]. Gastroenterol Hepatol. 2011;34:524-531. [PMID: 21940068 DOI: 10.1016/j.gastrohep.2011.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
489 Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260:329-340. [PMID: 24096763 DOI: 10.1097/sla.0000000000000236] [Cited by in Crossref: 215] [Cited by in F6Publishing: 132] [Article Influence: 35.8] [Reference Citation Analysis]
490 Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, De Simone P, Filipponi F, Bartolozzi C. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation. Radiology. 2010;255:289-300. [PMID: 20308465 DOI: 10.1148/radiol.09090927] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
491 Cao W, Li J, Hu C, Shen J, Liu X, Xu Y, Ye Z. Symptom clusters and symptom interference of HCC patients undergoing TACE: a cross-sectional study in China. Support Care Cancer 2013;21:475-83. [DOI: 10.1007/s00520-012-1541-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
492 Huo T, Huang Y, Wu J, Lee P, Chang F, Lee S. Persistent retention of acetic acid is associated with complete tumour necrosis in patients with hepatocellular carcinoma undergoing percutaneous acetic acid injection. Scandinavian Journal of Gastroenterology 2009;39:168-73. [DOI: 10.1080/00365520310008269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
493 Corona-Villalobos CP, Halappa VG, Bonekamp S, Eng J, Reyes D, Cosgrove D, Rastegar N, Pan L, Pawlik TM, Kamel IR. Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma. Invest Radiol. 2015;50:283-289. [PMID: 25396692 DOI: 10.1097/rli.0000000000000112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
494 Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee WC, Chen MF, Tsai CN. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol. 2012;19 Suppl 3:S455-S463. [PMID: 21822558 DOI: 10.1245/s10434-011-1946-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
495 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
496 Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, Abdalla EK. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11:1086-1092. [PMID: 16123959 DOI: 10.1002/lt.20472] [Cited by in Crossref: 401] [Cited by in F6Publishing: 353] [Article Influence: 25.1] [Reference Citation Analysis]
497 Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer. 2005;92:1862-1868. [PMID: 15870713 DOI: 10.1038/sj.bjc.6602590] [Cited by in Crossref: 115] [Cited by in F6Publishing: 107] [Article Influence: 7.2] [Reference Citation Analysis]
498 Zanus G, Boetto R, Gringeri E, Vitale A, D'Amico F, Carraro A, Bassi D, Bonsignore P, Noaro G, Mescoli C, Rugge M, Angeli P, Senzolo M, Burra P, Feltracco P, Cillo U. Microwave thermal ablation for hepatocarcinoma: Six liver transplantation cases. Transplant Proc. 2011;43:1091-1094. [PMID: 21620060 DOI: 10.1016/j.transproceed.2011.02.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
499 Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, Tono N, Fassina G, Cavalletto L, Gatta A. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer. 2006;119:735-740. [PMID: 16550605 DOI: 10.1002/ijc.21908] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
500 Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford). 2003;5:243-250. [PMID: 18332995 DOI: 10.1080/13651820310015833] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 7.7] [Reference Citation Analysis]
501 Chung M, Wang S, Lin C. Symptom Clusters and Impact of Fatigue and Sleep Disturbance on Symptom Experiences of Hepatoma Patients in Taiwan. Cancer Nurs 2017;40:403-11. [DOI: 10.1097/ncc.0000000000000417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
502 Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, Negi S, Awan Z, Aikin R, Kwan J, Amre R, Tabaries S, Hassanain M, Seidah NG, Maluccio M, Siegel P, Metrakos P. Decreased PCSK9 expression in human hepatocellular carcinoma. BMC Gastroenterol 2015;15:176. [PMID: 26674961 DOI: 10.1186/s12876-015-0371-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
503 Connolly GC, Chen R, Hyrien O, Mantry P, Bozorgzadeh A, Abt P, Khorana AA. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res. 2008;122:299-306. [PMID: 18045666 DOI: 10.1016/j.thromres.2007.10.009] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 4.5] [Reference Citation Analysis]
504 Li J, Huang L, Yan J, Qiu M, Yan Y. Liver resection for hepatocellular carcinoma: personal experiences in a series of 1330 consecutive cases in China. ANZ J Surg 2018;88:E713-7. [PMID: 29363237 DOI: 10.1111/ans.14381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
505 Huo TI, Lui WY, Huang YH, Chau GY, Wu JC, Lee PC, Chang FY, Lee SD. Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol. 2003;98:2293-2298. [PMID: 14572582 DOI: 10.1111/j.1572-0241.2003.07688.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
506 Wang J, Zhang S, Li Z, Yang J, Huang C, Liang R, Liu Z, Zhou R. 1H-NMR-based metabolomics of tumor tissue for the metabolic characterization of rat hepatocellular carcinoma formation and metastasis. Tumor Biol 2011;32:223-31. [DOI: 10.1007/s13277-010-0116-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
507 Liu P, Lee Y, Hsu C, Hsia C, Huang Y, Chiou Y, Lin H, Huo T. Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status. J Gastrointest Surg 2014;18:1623-31. [DOI: 10.1007/s11605-014-2546-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
508 Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC 2nd. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107:544-549. [PMID: 23090720 DOI: 10.1002/jso.23280] [Cited by in Crossref: 206] [Cited by in F6Publishing: 176] [Article Influence: 22.9] [Reference Citation Analysis]
509 Scatton O, Zalinski S, Terris B, Lefevre JH, Casali A, Massault PP, Conti F, Calmus Y, Soubrane O. Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation. Liver Transpl. 2008;14:779-788. [PMID: 18508370 DOI: 10.1002/lt.21431] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 4.8] [Reference Citation Analysis]
510 Ng KK, Vauthey J, Pawlik TM, Lauwers GY, Regimbeau J, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney DM, Ng IO, Fan ST, Poon RT. Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database. Ann Surg Oncol 2005;12:364-73. [DOI: 10.1245/aso.2005.06.004] [Cited by in Crossref: 167] [Cited by in F6Publishing: 80] [Article Influence: 10.4] [Reference Citation Analysis]
511 Zhang XP, Chai ZT, Gao YZ, Chen ZH, Wang K, Shi J, Guo WX, Zhou TF, Ding J, Cong WM, Xie D, Lau WY, Cheng SQ. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. HPB (Oxford) 2019;21:1687-96. [PMID: 31153833 DOI: 10.1016/j.hpb.2019.04.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
512 Armengol C, Boix L, Bachs O, Solé M, Fuster J, Sala M, Llovet JM, Rodés J, Bruix J. p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. J Hepatol. 2003;38:591-597. [PMID: 12713869 DOI: 10.1016/s0168-8278(03)00025-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
513 Li J, Huang L, Liu CF, Cao J, Yan JJ, Xu F, Wu MC, Yan YQ. Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma: a case-control study. World J Gastroenterol. 2014;20:9121-9127. [PMID: 25083085 DOI: 10.3748/wjg.v20.i27.9121] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
514 Parikh ND, Marshall VD, Green M, Lawrence TS, Razumilava N, Owen D, Singal AG, Feng M. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare. J Med Imaging Radiat Oncol 2018;62:673-81. [PMID: 29877615 DOI: 10.1111/1754-9485.12754] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
515 Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. The Lancet Oncology 2004;5:409-18. [DOI: 10.1016/s1470-2045(04)01508-6] [Cited by in Crossref: 117] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
516 Giannelli G, Marinosci F, Trerotoli P, Volpe A, Quaranta M, Dentico P, Antonaci S. SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int J Cancer. 2005;117:506-509. [PMID: 15906357 DOI: 10.1002/ijc.21189] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
517 Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006;25:3848-3856. [PMID: 16799626 DOI: 10.1038/sj.onc.1209548] [Cited by in Crossref: 109] [Cited by in F6Publishing: 93] [Article Influence: 7.3] [Reference Citation Analysis]
518 Shi JH, Line PD. Effect of liver regeneration on malignant hepatic tumors. World J Gastroenterol. 2014;20:16167-16177. [PMID: 25473170 DOI: 10.3748/wjg.v20.i43.16167] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
519 Tognolini A, Louie JD, Hwang GL, Hofmann LV, Sze DY, Kothary N. Utility of C-arm CT in patients with hepatocellular carcinoma undergoing transhepatic arterial chemoembolization. J Vasc Interv Radiol. 2010;21:339-347. [PMID: 20133156 DOI: 10.1016/j.jvir.2009.11.007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
520 Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. [PMID: 19908093 DOI: 10.1007/s00270-099-9711-7] [Reference Citation Analysis]
521 Zavaglia C, Corso R, Rampoldi A, Vinci M, Belli LS, Vangeli M, Solcia M, Castoldi C, Prisco C, Vanzulli A, Pinzello G. Is percutaneous radiofrequency thermal ablation of hepatocellular carcinoma a safe procedure?: . European Journal of Gastroenterology & Hepatology 2008;20:196-201. [DOI: 10.1097/meg.0b013e3282f1cc4a] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
522 Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G, Bargellini I, Petruzzi P, Massa Saluzzo C, Crespi S. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol. 2008;31:1141-1149. [PMID: 18696150 DOI: 10.1007/s00270-008-9409-2] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 6.5] [Reference Citation Analysis]
523 Massani M, Stecca T, Ruffolo C, Bassi N. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates Surg 2017;69:67-73. [PMID: 28097502 DOI: 10.1007/s13304-017-0414-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
524 Tremblay MP, Armero VE, Allaire A, Boudreault S, Martenon-Brodeur C, Durand M, Lapointe E, Thibault P, Tremblay-Létourneau M, Perreault JP, Scott MS, Bisaillon M. Global profiling of alternative RNA splicing events provides insights into molecular differences between various types of hepatocellular carcinoma. BMC Genomics 2016;17:683. [PMID: 27565572 DOI: 10.1186/s12864-016-3029-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
525 Rosenthal P. Hepatocarcinoma in Viral and Metabolic Liver Disease. Journal of Pediatric Gastroenterology & Nutrition 2008;46:370-5. [DOI: 10.1097/mpg.0b013e318158799b] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
526 Gilabert M, Raoul JL. Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. J Hepatocell Carcinoma 2018;5:91-8. [PMID: 30464931 DOI: 10.2147/JHC.S157413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
527 Ying ZL, Li XJ, Dang H, Wang F, Xu XY. Saikosaponin-d affects the differentiation, maturation and function of monocyte-derived dendritic cells. Exp Ther Med. 2014;7:1354-1358. [PMID: 24940438 DOI: 10.3892/etm] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
528 Yang MJ, An SY, Moon EJ, Lee MS, Hwang JA, Cheong JY, Won JH, Kim JK, Wang HJ, Cho SW. [Comparison of radiofrequency ablation and transarterial chemoembolization for the treatment of a single hepatocellular carcinoma smaller than 4 cm]. Korean J Hepatol. 2009;15:474-485. [PMID: 20037266 DOI: 10.3350/kjhep.2009.15.4.474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
529 Majno P, Giostra E, Mentha G. Management of hepatocellular carcinoma on the waiting list before liver transplantation: Time for controlled trials? Liver Transpl 2007;13:S27-35. [DOI: 10.1002/lt.21328] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
530 Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, Caralt T, Ayuso JR, Solé M, Sanchez M. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003;38:1034-1042. [PMID: 14512891 DOI: 10.1002/hep.1840380430] [Cited by in Crossref: 297] [Cited by in F6Publishing: 153] [Article Influence: 16.5] [Reference Citation Analysis]
531 Briceño J, Ciria R, de la Mata M. Donor-recipient matching: Myths and realities. Journal of Hepatology 2013;58:811-20. [DOI: 10.1016/j.jhep.2012.10.020] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
532 Truty MJ, Vauthey JN. Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol. 2010;17:1219-1225. [PMID: 20405326 DOI: 10.1245/s10434-010-0976-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
533 Lencioni R, Della Pina C, Bartolozzi C. Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma. Abdom Imaging 2005;30:401-8. [DOI: 10.1007/s00261-004-0254-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
534 Bonin S, Pascolo L, Crocé LS, Stanta G, Tiribelli C. Gene Expression of ABC Proteins in Hepatocellular Carcinoma, Perineoplastic Tissue, and Liver Diseases. Mol Med 2002;8:318-25. [DOI: 10.1007/bf03402158] [Cited by in Crossref: 37] [Article Influence: 1.9] [Reference Citation Analysis]
535 Giannini EG, Risso D, Testa R, Trevisani F, Di Nolfo MA, Del Poggio P, Benvegnù L, Ludovico Rapaccini G, Farinati F, Zoli M. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:1378-1384. [PMID: 17059899 DOI: 10.1016/j.cgh.2006.08.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
536 Hsu CY, Liu PH, Hsia CY, Lee YH, Al Juboori A, Lee RC, Lin HC, Huo TI. Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. Liver Int. 2016;36:1498-1506. [PMID: 26972815 DOI: 10.1111/liv.13114] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
537 Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
538 Hatzaras I, Bischof DA, Fahy B, Cosgrove D, Pawlik TM. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol 2014;21:758-66. [PMID: 24006095 DOI: 10.1245/s10434-013-3254-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
539 Karim ME, Tha KK, Othman I, Borhan Uddin M, Chowdhury EH. Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers. Pharmaceutics 2018;10:E65. [PMID: 29861465 DOI: 10.3390/pharmaceutics10020065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
540 Han K, Lee JT, Seong J. Treatment of non-resectable hepatocellular carcinoma: Non-resectable HCC. Journal of Gastroenterology and Hepatology 2002;17:S424-7. [DOI: 10.1046/j.1440-1746.17.s3.39.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
541 Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci 2019;24:86. [PMID: 31741658 DOI: 10.4103/jrms.JRMS_1017_18] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
542 Katsura Y, Wada H, Murakami M, Akita H, Hama N, Kawamoto K, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H. PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. Ann Surg Oncol 2013;20 Suppl 3:S517-26. [PMID: 23508585 DOI: 10.1245/s10434-013-2948-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
543 He P, Zhang HX, Sun CY, Chen CY, Jiang HQ. Overexpression of SASH1 Inhibits the Proliferation, Invasion, and EMT in Hepatocarcinoma Cells. Oncol Res 2016;24:25-32. [PMID: 27178819 DOI: 10.3727/096504016X14575597858609] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
544 Xiong YQ, Sun HC, Zhu XD, Zhang W, Zhuang PY, Zhang JB, Xu HX, Kong LQ, Wu WZ, Qin LX, Tang ZY. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression. J Cancer Res Clin Oncol 2011;137:505-12. [PMID: 20490863 DOI: 10.1007/s00432-010-0914-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
545 Fartoux L, Arrive L, Andreani T, Serfaty L, Chazouillères O, Tubiana J, Poupon R, Rosmorduc O. Treatment of small hepatocellular carcinoma with acetic acid percutaneous injection. Gastroentérologie Clinique et Biologique 2005;29:1213-9. [DOI: 10.1016/s0399-8320(05)82203-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
546 Cillo U, Navaglia F, Vitale A, Molari A, Basso D, Bassanello M, Brolese A, Zanus G, Montin U, D'amico F, Ciarleglio FA, Carraro A, Bridda A, Burra P, Carraro P, Plebani M, D'amico DF. Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. Clinica Chimica Acta 2004;347:129-38. [DOI: 10.1016/j.cccn.2004.04.032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
547 Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:S115-S120. [PMID: 14762851 DOI: 10.1002/lt.20034] [Cited by in Crossref: 459] [Cited by in F6Publishing: 401] [Article Influence: 27.0] [Reference Citation Analysis]
548 Stone MJ, Fulmer JM, Klintmalm GB. Transplantation for Primary Hepatic Malignancy. Transplantation of the Liver. Elsevier; 2005. pp. 211-31. [DOI: 10.1016/b978-0-7216-0118-2.50020-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
549 Bolog N, Pfammatter T, Müllhaupt B, Andreisek G, Weishaupt D. Double-contrast magnetic resonance imaging of hepatocellular carcinoma after transarterial chemoembolization. Abdom Imaging. 2008;33:313-323. [PMID: 17483983 DOI: 10.1007/s00261-007-9244-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
550 Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, Wu MC, Zhou WP. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014;61:82-88. [PMID: 24650695 DOI: 10.1016/j.jhep.2014.03.012] [Cited by in Crossref: 145] [Cited by in F6Publishing: 131] [Article Influence: 20.7] [Reference Citation Analysis]
551 Perry JF, Charlton B, Koorey DJ, Waugh RC, Gallagher PJ, Crawford MD, Verran DJ, McCaughan GW, Strasser SI. Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. Liver Int. 2007;27:1240-1248. [PMID: 17919236 DOI: 10.1111/j.1478-3231.2007.01569.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
552 Colagrande S, La Villa G, Bartolucci M, Lanini F, Barletta G, Villari N. Spiral computed tomography versus ultrasound in the follow-up of cirrhotic patients previously treated for hepatocellular carcinoma: a prospective study. J Hepatol 2003;39:93-8. [PMID: 12821049 DOI: 10.1016/s0168-8278(03)00159-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
553 Xu Q, Yan Y, Gu S, Mao K, Zhang J, Huang P, Zhou Z, Chen Z, Zheng S, Liang J, Lin Z, Wang J, Yan J, Xiao Z. A Novel Inflammation-Based Prognostic Score: The Fibrinogen/Albumin Ratio Predicts Prognoses of Patients after Curative Resection for Hepatocellular Carcinoma. J Immunol Res. 2018;2018:4925498. [PMID: 30027102 DOI: 10.1155/2018/4925498] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
554 Hidaka M, Eguchi S, Okudaira S, Takatsuki M, Tokai H, Soyama A, Nagayoshi S, Mochizuki S, Hamasaki K, Tajima Y, Kanematsu T. Multicentric occurrence and spread of hepatocellular carcinoma in whole explanted end-stage liver. Hepatology Research 2009;39:143-8. [DOI: 10.1111/j.1872-034x.2008.00443.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
555 Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, Sung KB, Gwon DI, Shin JH, Song HY. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol. 2011;22:917-923. [PMID: 21571545 DOI: 10.1016/j.jvir.2011.03.005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
556 Bonferoni MC, Gavini E, Rassu G, Maestri M, Giunchedi P. Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting. Nanomaterials (Basel) 2020;10:E870. [PMID: 32365938 DOI: 10.3390/nano10050870] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
557 Udoh U, Sanabria JD, Rajan PK, Banerjee M, Schade M, Sanabria JA, Smith G, Udoh G, Sodhi K, Pierre S, Shapiro JI, Sanabria JR. Non-Alcoholic Fatty Liver Disease Progression to Non-Alcoholic Steatohepatitis-Related Primary Liver Cancer. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 55-76. [DOI: 10.36255/exonpublications.livercancer.2021.ch3] [Reference Citation Analysis]
558 Kim HY, Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer. 2014;3:9-17. [PMID: 24804173 DOI: 10.1159/000343854] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
559 Gavilán JC, Ojeda G, Arnedo R, Puerta S. Predictive factors of risk of hepatocellular carcinoma in chronic hepatitis C. European Journal of Internal Medicine 2013;24:846-51. [DOI: 10.1016/j.ejim.2013.06.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
560 Liu L, Li NF, Zhang Q, Lin L. Hepatocellular carcinoma successfully treated with ALPPS and apatinib: A case report. World J Clin Cases 2019;7:2384-92. [PMID: 31531335 DOI: 10.12998/wjcc.v7.i16.2384] [Reference Citation Analysis]
561 Varela M, Sala M, Llovet JM, Bruix J. Natural history and prognostic prediction of patients with hepatocellular carcinoma: REVIEW: NATURAL HISTORY AND PROGNOSTIC PREDICTION. Alimentary Pharmacology & Therapeutics 2003;17:98-102. [DOI: 10.1046/j.1365-2036.17.s2.11.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
562 Bruix J, Fuster J, Llovet JM. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl. 2003;9:700-702. [PMID: 12827556 DOI: 10.1053/jlts.2003.50124] [Cited by in Crossref: 82] [Cited by in F6Publishing: 64] [Article Influence: 4.6] [Reference Citation Analysis]
563 Ferrer Puchol MD, la Parra C, Esteban E, Vaño M, Forment M, Vera A, Cosín O. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Radiologia 2011;53:246-53. [PMID: 21295802 DOI: 10.1016/j.rx.2010.07.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
564 Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003;37:1114-1121. [PMID: 12717392 DOI: 10.1053/jhep.2003.50195] [Cited by in Crossref: 271] [Cited by in F6Publishing: 234] [Article Influence: 15.1] [Reference Citation Analysis]
565 Wang Y, Zhang L, Li Y, Wang W. Computed tomography-guided percutaneous microwave ablation with artificial ascites for problematic hepatocellular tumors. Int J Hyperthermia 2020;37:256-62. [PMID: 32157926 DOI: 10.1080/02656736.2020.1736649] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
566 Mejia G, Gomez M, Serrano J, Garcia I, Tamayo M, Pareja F, Sousa J, Pascacio J, Gavilan F, Castell J, Vargas B, Bernardos A. Correlation Between the Radiologic and Histologic Size of Hepatocellular Carcinoma in Patients Eligible for Liver Transplantation. Transplantation Proceedings 2006;38:1394-5. [DOI: 10.1016/j.transproceed.2006.02.064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
567 Ikeda M, Ohkawa S, Okusaka T, Mitsunaga S, Kobayashi S, Morizane C, Suzuki I, Yamamoto S, Furuse J. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci. 2014;105:455-462. [PMID: 24521523 DOI: 10.1111/cas.12368] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
568 Chen L, Ho DW, Lee NP, Sun S, Lam B, Wong KF, Yi X, Lau GK, Ng EW, Poon TC. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol. 2010;17:2518-2525. [PMID: 20354800 DOI: 10.1245/s10434-010-1038-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
569 Fouzas I, Sotiropoulos G, Lang H, Nadalin S, Beckebaum S, Sgourakis G, Saner F, Radtke A, Papanikolaou V, Baba H, Paul A, Broelsch C, Malagó M. Living Donor Liver Transplantation for Hepatocellular Carcinoma in Patients Exceeding the UCSF Criteria. Transplantation Proceedings 2008;40:3185-8. [DOI: 10.1016/j.transproceed.2008.08.036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
570 Zhang J, Zhang M, Ma H, Song X, He L, Ye X, Li X. A meta-analysis of the prognostic significance of Golgi protein 73 in hepatocellular carcinoma in Chinese patients. Arch Med Sci 2020;16:1104-10. [PMID: 32863999 DOI: 10.5114/aoms.2019.83821] [Reference Citation Analysis]
571 Tian L, Yu Q, Gao XH, Wu J, Ma XL, Dai Q, Zhang CY, Zhou Y, Zhang YC, Pan BS, Zhou J, Fan J, Yang XR, Guo W. A new use for an old index: preoperative high-density lipoprotein predicts recurrence in patients with hepatocellular carcinoma after curative resections. Lipids Health Dis 2017;16:123. [PMID: 28651644 DOI: 10.1186/s12944-017-0509-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
572 Lepareur N, Garin E, Noiret N, Herry JY. A kit formulation for the labelling of lipiodol with generator-produced188Re. J Labelled Cpd Radiopharm 2004;47:857-67. [DOI: 10.1002/jlcr.863] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
573 Tian Y, Lyu H, He Y, Kanduri HK. Evaluating the Ability of the New Subclassification to Prognosticate Outcomes Following Hepatectomy for Patients with HBV-Related HCC. J Gastrointest Cancer 2019;50:400-7. [PMID: 29512001 DOI: 10.1007/s12029-018-0085-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
574 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Huo TI. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. Aliment Pharmacol Ther. 2012;36:551-559. [PMID: 22817677 DOI: 10.1111/j.1365-2036.2012.05226.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
575 Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240:102-107. [PMID: 15213625 DOI: 10.1097/01.sla.0000129672.51886.44] [Cited by in Crossref: 178] [Cited by in F6Publishing: 151] [Article Influence: 10.5] [Reference Citation Analysis]
576 Sun Y, Lin R, Dai J, Jin D, Wang SQ. Suppression of tumor growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice. Oligonucleotides 2006;16:365-74. [PMID: 17155911 DOI: 10.1089/oli.2006.16.365] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
577 Chen C, Lou T. Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget 2017;8:46691-703. [PMID: 28493839 DOI: 10.18632/oncotarget.17358] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 20.7] [Reference Citation Analysis]
578 Salmi A, Turrini R, Lanzani G, Savio A, Anglani L. Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis. Int J Med Sci 2008;5:327-32. [PMID: 18974861 DOI: 10.7150/ijms.5.327] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
579 Wang H, Li W. Recent update on comprehensive therapy for advanced hepatocellular carcinoma. WJGO 2021;13:845-55. [DOI: 10.4251/wjgo.v13.i8.845] [Reference Citation Analysis]
580 Mok WC, Wasser S, Tan T, Lim SG. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2012;18:3527-3536. [PMID: 22826617 DOI: 10.3748/wjg.v18.i27.3527] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
581 Sun Y, Yang H, Mao Y, Xu H, Zhang J, Li G, Lu X, Sang X, Zhao H, Zhong S, Huang J, Zhang H. Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol. 2011;26:1207-1212. [PMID: 21443671 DOI: 10.1111/j.1440-1746.2011.06733.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
582 Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-700. e3. [PMID: 24583061 DOI: 10.1053/j.gastro.2014.02.032] [Cited by in Crossref: 339] [Cited by in F6Publishing: 294] [Article Influence: 48.4] [Reference Citation Analysis]
583 Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. Eur Radiol 2016;26:3243-52. [PMID: 26762942 DOI: 10.1007/s00330-015-4168-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
584 Maluf DG, Stravitz RT, Williams B, Cotterell AH, Mas VR, Heuman D, Luketic V, Shiffman ML, Sterling R, Posner MP, Fisher RA. Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience. Transplant Proc 2007;39:153-9. [PMID: 17275495 DOI: 10.1016/j.transproceed.2006.10.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
585 Toshima T, Shirabe K, Matsumoto Y, Yoshiya S, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y. Autophagy enhances hepatocellular carcinoma progression by activation of mitochondrial β-oxidation. J Gastroenterol 2014;49:907-16. [DOI: 10.1007/s00535-013-0835-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
586 Stacy S, Hyder O, Cosgrove D, Herman JM, Kamel I, Geschwind JF, Gurakar A, Anders R, Cameron A, Pawlik TM. Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US. J Gastrointest Surg 2013;17:1600-8. [PMID: 23780638 DOI: 10.1007/s11605-013-2253-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
587 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 312] [Article Influence: 121.7] [Reference Citation Analysis]
588 Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:1061-9. [PMID: 28960360 DOI: 10.1111/apt.14342] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
589 Liang LJ, Hu WJ, Yin XY, Zhou Q, Peng BG, Li DM, Lu MD. Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal thrombectomy. World J Surg. 2008;32:627-631. [PMID: 18228094 DOI: 10.1007/s00268-007-9364-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
590 Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, Ascher NL, Roberts JP. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transpl. 2003;9:684-692. [PMID: 12827553 DOI: 10.1053/jlts.2003.50147] [Cited by in Crossref: 193] [Cited by in F6Publishing: 170] [Article Influence: 10.7] [Reference Citation Analysis]
591 Buijs M, Vossen JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, Geschwind JF. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience. Radiology 2008;249:346-54. [PMID: 18796686 DOI: 10.1148/radiol.2483071902] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
592 Yamanaka C, Wada H, Eguchi H, Hatano H, Gotoh K, Noda T, Yamada D, Asaoka T, Kawamoto K, Nagano H, Doki Y, Mori M. Clinical significance of CD13 and epithelial mesenchymal transition (EMT) markers in hepatocellular carcinoma. Jpn J Clin Oncol 2018;48:52-60. [PMID: 29145632 DOI: 10.1093/jjco/hyx157] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
593 Schulze-Bergkamen H, Fleischer B, Schuchmann M, Weber A, Weinmann A, Krammer PH, Galle PR. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 2006;6:232. [PMID: 17014711 DOI: 10.1186/1471-2407-6-232] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
594 Yuan SX, Yang F, Yang Y, Tao QF, Zhang J, Huang G, Yang Y, Wang RY, Yang S, Huo XS. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy. Hepatology. 2012;56:2231-2241. [PMID: 22706893 DOI: 10.1002/hep.25895] [Cited by in Crossref: 262] [Cited by in F6Publishing: 259] [Article Influence: 32.8] [Reference Citation Analysis]
595 Llovet JM. Evidence-based medicine in the treatment of hepatocellular carcinoma: Evidence-based treatment of HCC. Journal of Gastroenterology and Hepatology 2002;17:S428-33. [DOI: 10.1046/j.1440-1746.17.s3.40.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
596 Ye Z, Wu W, Qin Y, Hu J, Liu C, Seeberger PH, Yin J. An Integrated Therapeutic Delivery System for Enhanced Treatment of Hepatocellular Carcinoma. Adv Funct Mater 2018;28:1706600. [DOI: 10.1002/adfm.201706600] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 8.3] [Reference Citation Analysis]
597 Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol. 2009;193:1044-1052. [PMID: 19770328 DOI: 10.2214/ajr.08.1461] [Cited by in Crossref: 137] [Cited by in F6Publishing: 41] [Article Influence: 11.4] [Reference Citation Analysis]
598 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 87] [Article Influence: 2.4] [Reference Citation Analysis]
599 Xie ZB, Wang XB, Peng YC, Zhu SL, Ma L, Xiang BD, Gong WF, Chen J, You XM, Jiang JH, Li LQ, Zhong JH. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res. 2015;45:190-200. [PMID: 25388603 DOI: 10.1111/hepr.12450] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
600 Yokoi H, Isaji S, Yamagiwa K, Tabata M, Nemoto A, Sakurai H, Usui M, Uemoto S. The role of living-donor liver transplantation in surgical treatment for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006;13:123-30. [DOI: 10.1007/s00534-005-1018-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
601 Xu M, Qian G, Xie F, Shi C, Yan L, Yu L, Zheng T, Wei L, Yang J. Expression of epithelial cell adhesion molecule associated with elevated ductular reactions in hepatocellar carcinoma. Clinics and Research in Hepatology and Gastroenterology 2014;38:699-705. [DOI: 10.1016/j.clinre.2014.04.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
602 Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer. 2009;9:271. [PMID: 19656391 DOI: 10.1186/1471-2407-9-271] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
603 Santambrogio R, Costa M, Barabino M, Opocher E. Laparoscopic radiofrequency of hepatocellular carcinoma using ultrasound-guided selective intrahepatic vascular occlusion. Surg Endosc 2008;22:2051-5. [PMID: 18247089 DOI: 10.1007/s00464-008-9751-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
604 Guglielmi A, Ruzzenente A, Sandri M, Pachera S, Pedrazzani C, Tasselli S, Iacono C. Radio frequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival. J Gastrointest Surg. 2007;11:143-149. [PMID: 17390163 DOI: 10.1007/s11605-006-0082-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
605 Giannelli G, Marinosci F, Sgarra C, Lupo L, Dentico P, Antonaci S. Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. Int J Cancer 2005;116:579-83. [PMID: 15825162 DOI: 10.1002/ijc.20847] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
606 Jia Z, Tian F, Jiang G. Ruptured hepatic carcinoma after transcatheter arterial chemoembolization. Curr Ther Res Clin Exp. 2013;74:41-43. [PMID: 24384870 DOI: 10.1016/j.curtheres.2012.12.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
607 Yoon SH, Choi SW, Nam SW, Lee KB, Nam JW. Preoperative immune landscape predisposes adverse outcomes in hepatocellular carcinoma patients with liver transplantation. NPJ Precis Oncol 2021;5:27. [PMID: 33772139 DOI: 10.1038/s41698-021-00167-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
608 Hiatt JR, Carmody IC, Busuttil RW. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?--no, never. J Hepatol 2005;43:573-7. [PMID: 16112768 DOI: 10.1016/j.jhep.2005.07.017] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
609 Siegel AB, Mcbride RB, El-serag HB, Hershman DL, Brown RS, Renz JF, Emond J, Neugut AI. Racial Disparities in Utilization of Liver Transplantation for Hepatocellular Carcinoma in the United States, 1998–2002. Am J Gastroenterol 2008;103:120-7. [DOI: 10.1111/j.1572-0241.2007.01634.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
610 Choi SJ, Kim J, Seo J, Kim HS, Lee JM, Park H. Parametric response mapping of dynamic CT as an imaging biomarker to distinguish viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Abdom Imaging 2014;39:518-25. [PMID: 24519566 DOI: 10.1007/s00261-014-0087-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
611 Kooby DA, Jarnagin WR. Surgical management of hepatic malignancy. Cancer Invest. 2004;22:283-303. [PMID: 15199611 DOI: 10.1081/cnv-120030217] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
612 Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33:532-540. [PMID: 19847482 DOI: 10.1007/s00270-009-9728-y] [Cited by in Crossref: 92] [Cited by in F6Publishing: 66] [Article Influence: 7.7] [Reference Citation Analysis]
613 Abdelaziz AO, Nabeel MM, Elbaz TM, Shousha HI, Hassan EM, Mahmoud SH, Rashed NA, Ibrahim MM, Abdelmaksoud AH. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scand J Gastroenterol. 2015;50:479-484. [PMID: 25592058 DOI: 10.3109/00365521.2014.1003397] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
614 Chang S, Suh K, Yi N, Lee K, Kim B, Jang J. Predicting the Prognosis of Hepatocellular Carcinoma Using Gene Expression. Journal of Surgical Research 2011;171:524-31. [DOI: 10.1016/j.jss.2010.05.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
615 Zalinski S, Scatton O, Randone B, Vignaux O, Dousset B. Complete hepatocellular carcinoma necrosis following sequential porto-arterial embolization. World J Gastroenterol. 2008;14:6869-6872. [PMID: 19058317 DOI: 10.3748/wjg.14.6869] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
616 Torzilli G, Belghiti J, Makuuchi M. Differences and similarities in the approach to hepatocellular carcinoma between Eastern and Western institutions. Liver Transpl 2004;10:S1-2. [PMID: 14762830 DOI: 10.1002/lt.20032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
617 Fujii K, Kondo T, Yokoo H, Yamada T, Iwatsuki K, Hirohashi S. Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye. Proteomics. 2005;5:1411-1422. [PMID: 15751005 DOI: 10.1002/pmic.200401004] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
618 Zhuang H, Zhou Z, Ma Z, Huang S, Gong Y, Zhang Z, Hou B, Yu W, Zhang C. Prognostic Stratification Based on a Novel Nomogram for Solitary Large Hepatocellular Carcinoma After Curative Resection. Front Oncol 2020;10:556489. [PMID: 33312945 DOI: 10.3389/fonc.2020.556489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
619 Mela M, Mancuso A, Burroughs AK. Review article: hepatocellular carcinoma: indications for liver transplantation. Aliment Pharmacol Ther. 2003;17 Suppl 2:130-137. [PMID: 12786624 DOI: 10.1046/j.1365-2036.17.s2.16.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
620 Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'amico F, Ciarleglio FA, Bridda A, Francesco D'amico D. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of Hepatology 2006;44:723-31. [DOI: 10.1016/j.jhep.2005.12.015] [Cited by in Crossref: 275] [Cited by in F6Publishing: 243] [Article Influence: 18.3] [Reference Citation Analysis]
621 Fang KC, Kao WY, Su CW, Chen PC, Lee PC, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. Liver Cancer. 2018;7:335-358. [PMID: 30488023 DOI: 10.1159/000487407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
622 Hoki T, Katsuta E, Yan L, Takabe K, Ito F. Low DMT1 Expression Associates With Increased Oxidative Phosphorylation and Early Recurrence in Hepatocellular Carcinoma. J Surg Res 2019;234:343-52. [PMID: 30527495 DOI: 10.1016/j.jss.2018.11.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
623 Suh KS, Cho EH, Lee HW, Shin WY, Yi NJ, Lee KU. Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis. 2007;25:329-333. [PMID: 17960068 DOI: 10.1159/000106913] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
624 Wang J, Feng S, Lin J, Zeng Y, Li L, Huang Z, Li B, Zeng H, Chen R. Serum albumin and globulin analysis for hepatocellular carcinoma detection avoiding false-negative results from alpha-fetoprotein test negative subjects. Appl Phys Lett 2013;103:204106. [DOI: 10.1063/1.4830047] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
625 Dai T, Zhang D, Cai M, Wang C, Wu Z, Ying Z, Wu J, Li M, Xie D, Li J. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-κB pathway. J Pathol. 2015;235:490-501. [PMID: 25385148 DOI: 10.1002/path.4479] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
626 Yeh CC, Hsu CH, Shao YY, Ho WC, Tsai MH, Feng WC, Chow LP. Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer. Mol Cell Proteomics. 2015;14:1527-1545. [PMID: 25850433 DOI: 10.1074/mcp.m114.046417] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
627 García-valdecasas J, Fuster J, Charco R, Bombuy E, Fondevila C, Navasa M, Rodríguez-laiz G, Ferrer J, Amador M, Llovet J, Forns X, Rimola A. Trasplante hepático de donante vivo en adultos. Análisis de los 30 primeros casos. Gastroenterología y Hepatología 2003;26:525-30. [DOI: 10.1016/s0210-5705(03)70406-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
628 Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K, Iio E, Miyaki T, Nomura T, Sobue S, Sano H, Hasegawa I, Ohno T, Takahashi Y, Orito E, Joh T. Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma. Cancer Manag Res 2012;4:423-9. [PMID: 23293537 DOI: 10.2147/CMAR.S38684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
629 Hanje AJ, Yao FY. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant 2008;13:234-40. [PMID: 18685309 DOI: 10.1097/MOT.0b013e3282fc2633] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
630 Ochiai T, Sonoyama T, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Ueda Y, Otsuji E, Itoi H, Hagiwara A. Poor prognostic factors of hepatectomy in patients with resectable small hepatocellular carcinoma and cirrhosis. J Cancer Res Clin Oncol. 2004;130:197-202. [PMID: 14770307 DOI: 10.1007/s00432-003-0533-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
631 Varshosaz J, Farzan M. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol 2015;21:12022-41. [PMID: 26576089 DOI: 10.3748/wjg.v21.i42.12022] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
632 Lin S, Zhuang J, Zhu L, Jiang Z. Matrine inhibits cell growth, migration, invasion and promotes autophagy in hepatocellular carcinoma by regulation of circ_0027345/miR-345-5p/HOXD3 axis. Cancer Cell Int 2020;20:246. [PMID: 32549793 DOI: 10.1186/s12935-020-01293-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
633 Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127:S277-S282. [PMID: 15508095 DOI: 10.1053/j.gastro.2004.09.042] [Cited by in Crossref: 132] [Cited by in F6Publishing: 116] [Article Influence: 7.8] [Reference Citation Analysis]
634 Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, Ikai I. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008;49:589-594. [PMID: 18620773 DOI: 10.1016/j.jhep.2008.05.018] [Cited by in Crossref: 124] [Cited by in F6Publishing: 113] [Article Influence: 9.5] [Reference Citation Analysis]
635 Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799-805. [PMID: 19387322 DOI: 10.1097/sla.0b013e3181a38eb5] [Cited by in Crossref: 185] [Cited by in F6Publishing: 72] [Article Influence: 15.4] [Reference Citation Analysis]
636 Jeon MJ, Gordon AC, Larson AC, Chung JW, Kim YI, Kim DH. Transcatheter intra-arterial infusion of doxorubicin loaded porous magnetic nano-clusters with iodinated oil for the treatment of liver cancer. Biomaterials 2016;88:25-33. [PMID: 26938029 DOI: 10.1016/j.biomaterials.2016.02.021] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
637 Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES, Kaseb A. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med. 2014;11:e1001770. [PMID: 25536056 DOI: 10.1371/journal.pmed.1001770] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
638 Jin B, Wang D, Lewandowski RJ, Riaz A, Ryu RK, Sato KT, Larson AC, Salem R, Omary RA. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol. 2011;196:919-928. [PMID: 21427346 DOI: 10.2214/AJR.10.4770] [Cited by in Crossref: 40] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
639 Wang J, Lian Y, Gu Y, Wang H, Gu L, Huang Y, Zhou L, Huang Y. Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells. Oncotarget 2017;8:105047-60. [PMID: 29285232 DOI: 10.18632/oncotarget.22086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
640 Lee CM, Choi SH, Byun JH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm. Hepatol Int 2021;15:676-84. [PMID: 33956288 DOI: 10.1007/s12072-021-10190-x] [Reference Citation Analysis]
641 Yan X, Chua MS, He J, So SK. Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo. Mol Cancer 2008;7:19. [PMID: 18269767 DOI: 10.1186/1476-4598-7-19] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
642 Park JG, Tak WY, Park SY, Kweon YO, Jang SY, Lee SH, Lee YR, Jang SK, Hur K, Lee HJ. Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report. Oncol Lett 2017;14:4853-6. [PMID: 29085491 DOI: 10.3892/ol.2017.6788] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
643 Eom BW, Lee JH, Lee JS, Kim MJ, Ryu KW, Choi IJ, Cho SJ, Lee JY, Rhee J, Nam BH, Kim YW. Survival analysis of gastric cancer patients with tumor thrombus in the portal vein. J Surg Oncol 2012;105:310-5. [PMID: 21898415 DOI: 10.1002/jso.22083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
644 Bonadio I, Colle I, Geerts A, Smeets P, Berardi G, Praet M, Rogiers X, de Hemptinne B, Van Vlierberghe H, Troisi RI. Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asan criteria: long-term follow-up of a Western single institutional experience. Clin Transplant 2015;29:425-33. [DOI: 10.1111/ctr.12534] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
645 Bryant MK, Dorn DP, Zarzour J, Smith JK, Redden DT, Saddekni S, Abdel Aal AK, Gray SH, Eckhoff DE, Dubay DA. Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. HPB (Oxford). 2014;16:327-335. [PMID: 23980917 DOI: 10.1111/hpb.12149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
646 Han SX, Wang LJ, Zhao J, Zhang Y, Li M, Zhou X, Wang J, Zhu Q. 14-kDa Phosphohistidine phosphatase plays an important role in hepatocellular carcinoma cell proliferation. Oncol Lett 2012;4:658-64. [PMID: 23205079 DOI: 10.3892/ol.2012.802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
647 Tsai C, Chung HT, Chu W, Cheng JC. Radiation therapy for primary and metastatic tumors of the liver. J Radiat Oncol 2012;1:227-37. [DOI: 10.1007/s13566-012-0045-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
648 Yu SJ, Lee JH, Jang ES, Cho EJ, Kwak MS, Yoon JH, Lee HS, Kim CY, Kim YJ. Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. Radiology. 2013;267:638-647. [PMID: 23440326 DOI: 10.1148/radiol.13121498] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
649 Moriguchi M, Umemura A, Itoh Y. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. Clin J Gastroenterol 2016;9:184-90. [PMID: 27401471 DOI: 10.1007/s12328-016-0670-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
650 Petitjean A, Cavard C, Shi H, Tribollet V, Hainaut P, Caron de Fromentel C. The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells. Oncogene. 2005;24:512-519. [PMID: 15543231 DOI: 10.1038/sj.onc.1208215] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
651 Mabed M, Esmaeel M, El-khodary T, Awad M, Amer T. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. European Journal of Cancer Care 2009;18:492-9. [DOI: 10.1111/j.1365-2354.2008.00984.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
652 Li JX, Wu H, Huang JW, Zeng Y. The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. J Formos Med Assoc. 2012;111:510-515. [PMID: 23021508 DOI: 10.1016/j.jfma.2011.05.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
653 McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res. 2006;136:125-135. [PMID: 17023002 DOI: 10.1016/j.jss.2006.04.013] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 5.1] [Reference Citation Analysis]
654 Guo W, Chen S, Wu Z, Zhuang W, Yang J. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Technol Cancer Res Treat 2020;19:1533033820965587. [PMID: 33089769 DOI: 10.1177/1533033820965587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
655 Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004;240:451-459; discussion 459-461. [PMID: 15319716 DOI: 10.1097/01.2l1.0000137129.98894.42] [Reference Citation Analysis]
656 Kang JW, Kim JH, Ko GY, Gwon DI, Yoon HK, Sung KB. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol. 2012;53:545-550. [PMID: 22547388 DOI: 10.1258/ar.2012.110476] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
657 González HD, Figueras J. Surgical treatment for hepatocellular carcinoma in cirrhotic patients. Guide to the selection and decision-making process in a context of multimodal strategy. Clin Transl Oncol 2009;11:20-7. [DOI: 10.1007/s12094-009-0306-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
658 Broelsch CE, Frilling A, Malago M. Hepatoma—resection or transplantation. Surgical Clinics of North America 2004;84:495-511. [DOI: 10.1016/j.suc.2003.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
659 Yang T, Lau WY, Zhang H, Huang B, Lu JH, Wu MC. Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective. World J Gastroenterol 2015;21:8256-61. [PMID: 26217077 DOI: 10.3748/wjg.v21.i27.8256] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
660 Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg. 2006;202:155-168. [PMID: 16377509 DOI: 10.1016/j.jamcollsurg.2005.06.263] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
661 Takahashi H, Kawaguchi T, Yan L, Peng X, Qi Q, Morris LGT, Chan TA, Tsung A, Otsuji E, Takabe K. Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1221. [PMID: 32414098 DOI: 10.3390/cancers12051221] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
662 Higashi T, Hayashi H, Kaida T, Arima K, Takeyama H, Taki K, Izumi D, Tokunaga R, Kosumi K, Nakagawa S, Okabe H, Imai K, Nitta H, Hashimoto D, Chikamoto A, Beppu T, Baba H. Prognostic Impact of Visceral Fat Amount and Branched-Chain Amino Acids (BCAA) in Hepatocellular Carcinoma. Ann Surg Oncol 2015;22 Suppl 3:S1041-7. [PMID: 26305023 DOI: 10.1245/s10434-015-4796-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
663 Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M. Reply to Letter: “A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group”: When the Study Setting “Ignores” the Patients. Ann Surg. 2015;262:e30-e31. [PMID: 24253157 DOI: 10.1097/sla.0000000000000382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
664 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:159-69. [DOI: 10.1038/ncpgasthep1357] [Cited by in Crossref: 48